
<html lang="en"     class="pb-page"  data-request-id="6dad7138-b0c9-494e-af09-be62d1d51055"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;article:article:10.1021/acs.jmedchem.8b00346;journal:journal:jmcmar;page:string:Article/Chapter View;issue:issue:10.1021/jmcmar.2018.61.issue-13;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation" /></meta><meta name="dc.Creator" content="Yongjia  Hao" /></meta><meta name="dc.Creator" content="Jiankun  Lyu" /></meta><meta name="dc.Creator" content="Rong  Qu" /></meta><meta name="dc.Creator" content="Yi  Tong" /></meta><meta name="dc.Creator" content="Deheng  Sun" /></meta><meta name="dc.Creator" content="Fang  Feng" /></meta><meta name="dc.Creator" content="Linjiang  Tong" /></meta><meta name="dc.Creator" content="Tingyuan  Yang" /></meta><meta name="dc.Creator" content="Zhenjiang  Zhao" /></meta><meta name="dc.Creator" content="Lili  Zhu" /></meta><meta name="dc.Creator" content="Jian  Ding" /></meta><meta name="dc.Creator" content="Yufang  Xu" /></meta><meta name="dc.Creator" content="Hua  Xie" /></meta><meta name="dc.Creator" content="Honglin  Li" /></meta><meta name="dc.Description" content="First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EG..." /></meta><meta name="Description" content="First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EG..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 15, 2018" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b00346" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2018 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00346" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b00346" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b00346" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b00346" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0012.jpeg" /></meta><meta property="og:description" content="First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR activating mutations. However, their clinical benefit was limited by the emergence of acquired resistance mutations. In most cases (approximately 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation. Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR. Herein, a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives were designed and synthesized, among which the most potent compound 20g not only demonstrated significant inhibitory activity and selectivity for EGFRL858R/T790M and H1975 cells in vitro but also displayed outstanding antitumor efficiency in H1975 xenograft mouse model. The encouraging mutant-selective results at both in vitro and in vivo levels suggested that 20g might be used as a promising lead compound for further structural optimization as potent and selective EGFRL858R/T790M inhibitors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b00346"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b00346">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b00346&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b00346&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b00346&amp;href=/doi/10.1021/acs.jmedchem.8b00346" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2018</span><span class="cit-fg-volume">, 61</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 5609-5622</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/61/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b00328" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b00375" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yongjia Hao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yongjia Hao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div><div class="loa-info-affiliations-info">School of Pharmacy, Guizhou University of Chinese Medicine, Guiyang 550025, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yongjia++Hao">Yongjia Hao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jiankun Lyu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jiankun Lyu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jiankun++Lyu">Jiankun Lyu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rong Qu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rong Qu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rong++Qu">Rong Qu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yi Tong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yi Tong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yi++Tong">Yi Tong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Deheng Sun</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Deheng Sun</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Deheng++Sun">Deheng Sun</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fang Feng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fang Feng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fang++Feng">Fang Feng</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linjiang Tong</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linjiang Tong</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linjiang++Tong">Linjiang Tong</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tingyuan Yang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tingyuan Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tingyuan++Yang">Tingyuan Yang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Zhenjiang Zhao</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenjiang Zhao</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenjiang++Zhao">Zhenjiang Zhao</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lili Zhu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lili Zhu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lili++Zhu">Lili Zhu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jian Ding</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jian Ding</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jian++Ding">Jian Ding</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yufang Xu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yufang Xu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><span class="conrtib-corresp"><strong>*</strong>For Y.X.: phone, +86-21-64251399; E-mail, <a href="/cdn-cgi/l/email-protection#68110e101d280d0b1d1b1c460d0c1d460b06"><span class="__cf_email__" data-cfemail="760f100e0336131503050258131203581518">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yufang++Xu">Yufang Xu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Hua Xie</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Hua Xie</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Division of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div></div><span class="conrtib-corresp"><strong>*</strong>For H.X.: phone, +86-21-50805897; E-mail, <a href="/cdn-cgi/l/email-protection#6109190804210b05080f064f0509124f0e1306"><span class="__cf_email__" data-cfemail="147c6c7d71547e707d7a733a707c673a7b6673">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Hua++Xie">Hua Xie</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Honglin Li</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Honglin Li</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Shanghai Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor Engineering, School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China</div></div><span class="conrtib-corresp"><strong>*</strong>For H.L.: phone/fax, +86-21-64250213; E-mail, <a href="/cdn-cgi/l/email-protection#c4aca8a8ad84a1a7b1b7b0eaa1a0b1eaa7aa"><span class="__cf_email__" data-cfemail="e0888c8c89a08583959394ce858495ce838e">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Honglin++Li">Honglin Li</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2270-1900" title="Orcid link">http://orcid.org/0000-0003-2270-1900</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00346&amp;href=/doi/10.1021%2Facs.jmedchem.8b00346" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2018</span></span><span class="cit-volume">, 61</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 5609–5622</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 15, 2018</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>4 March 2018</li><li><span class="item_label"><b>Published</b> online</span>15 June 2018</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 July 2018</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00346</a></div><div class="article_header-article-copyright"><strong>Copyright © 2018 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5609%26pageCount%3D14%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYongjia%2BHao%252C%2BJiankun%2BLyu%252C%2BRong%2BQu%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D61%26issueNum%3D13%26contentID%3Dacs.jmedchem.8b00346%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BPyrimido%255B4%252C5-d%255Dpyrimidine-2%252C4%25281H%252C3H%2529-diones%2Bas%2BPotent%2Band%2BSelective%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BInhibitors%2Bagainst%2BL858R%252FT790M%2BResistance%2BMutation%26numPages%3D14%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5622%26publicationDate%3DJuly%2B2018">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b00346"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2804</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b00346" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yongjia&quot;,&quot;last_name&quot;:&quot;Hao&quot;},{&quot;first_name&quot;:&quot;Jiankun&quot;,&quot;last_name&quot;:&quot;Lyu&quot;},{&quot;first_name&quot;:&quot;Rong&quot;,&quot;last_name&quot;:&quot;Qu&quot;},{&quot;first_name&quot;:&quot;Yi&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Deheng&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Fang&quot;,&quot;last_name&quot;:&quot;Feng&quot;},{&quot;first_name&quot;:&quot;Linjiang&quot;,&quot;last_name&quot;:&quot;Tong&quot;},{&quot;first_name&quot;:&quot;Tingyuan&quot;,&quot;last_name&quot;:&quot;Yang&quot;},{&quot;first_name&quot;:&quot;Zhenjiang&quot;,&quot;last_name&quot;:&quot;Zhao&quot;},{&quot;first_name&quot;:&quot;Lili&quot;,&quot;last_name&quot;:&quot;Zhu&quot;},{&quot;first_name&quot;:&quot;Jian&quot;,&quot;last_name&quot;:&quot;Ding&quot;},{&quot;first_name&quot;:&quot;Yufang&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Hua&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Honglin&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2018&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;61&quot;,&quot;pages&quot;:&quot;5609-5622&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b00346&quot;},&quot;abstract&quot;:&quot;First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR activating mutations. However, their clinical benefit was limited by the emergence of acquired resistance mutations. In most cases (approximately 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation. Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR. Herein, a series of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives were designed and synthesized, among which the most potent compound 20g not only demonstrated significant inhibitory activity and selectivity for EGFRL858R/T790M and H1975 cells in vitro but also displayed outstanding antitumor efficiency in H1975 xenograft mouse model. The encouraging mutant-selective results at both in vitro and in vivo levels suggested that 20g might be used a&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00346&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00346" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00346&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00346" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b00346&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00346" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b00346&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b00346&amp;href=/doi/10.1021/acs.jmedchem.8b00346" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b00346" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b00346" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b00346%26sid%3Dliteratum%253Aachs%26pmid%3D29906114%26genre%3Darticle%26aulast%3DHao%26date%3D2018%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BPyrimido%255B4%252C5-d%255Dpyrimidine-2%252C4%25281H%252C3H%2529-diones%2Bas%2BPotent%2Band%2BSelective%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%2BInhibitors%2Bagainst%2BL858R%252FT790M%2BResistance%2BMutation%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D61%26issue%3D13%26spage%3D5609%26epage%3D5622%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (7)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/61/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/jmcmar.2018.61.issue-13/20180712/jmcmar.2018.61.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">First-generation epidermal growth factor receptor (EGFR) inhibitors, gefitinib and erlotinib, have achieved initially marked clinical efficacy for nonsmall cell lung cancer (NSCLC) patients with EGFR activating mutations. However, their clinical benefit was limited by the emergence of acquired resistance mutations. In most cases (approximately 60%), the resistance was caused by the secondary EGFR T790M gatekeeper mutation. Thus, it is still desirable to develop novel third-generation EGFR inhibitors to overcome T790M mutation while sparing wild-type (WT) EGFR. Herein, a series of pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione derivatives were designed and synthesized, among which the most potent compound <b>20g</b> not only demonstrated significant inhibitory activity and selectivity for EGFR<sup>L858R/T790M</sup> and H1975 cells in vitro but also displayed outstanding antitumor efficiency in H1975 xenograft mouse model. The encouraging mutant-selective results at both in vitro and in vivo levels suggested that <b>20g</b> might be used as a promising lead compound for further structural optimization as potent and selective EGFR<sup>L858R/T790M</sup> inhibitors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_48442" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_48442" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer, especially nonsmall cell lung cancer (NSCLC), is one of the most prevalent malignant tumors and also a major health problem worldwide, whose five-year survival rate is less than 15% after diagnosis.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> It is well-known that the epidermal growth factor receptor (EGFR, also known as ErbB1, HER1)-mediated signaling pathways are essential for various biological processes and cancers development and progression, such as cell proliferation, adhesion, migration, differentiation, and survival.<a onclick="showRef(event, 'ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref2 ref3 ref4">(2−4)</a> Thus, the EGFR tyrosine kinase has been proven to be an attractive and clinically validated drug target in cancer therapy, in particular for NSCLC treatment. First-generation reversible and quinazoline-based EGFR tyrosine kinase inhibitors (TKIs), including gefitinib (<b>1</b>) and erlotinib (<b>2</b>), have received approval from U.S. Food and Drug Administration (FDA) for the treatment of NSCLC in 2003 and 2004, respectively (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>),<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> despite the clinical efficacy of the two drugs having been well established for NSCLC patients with the most common EGFR activating mutations such as L858R (activating mutation in exon 21) and del E746–A750 (deletions in exon 19).<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Unfortunately, a secondary T790M point mutation (the substitution threonine790 with methionine residue) at the gatekeeper position of EGFR has caused approximately 60% NSCLC patients who initially responded to the treatment of first-generation EGFR inhibitors to develop acquired resistance after a median of 10–14 months.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Occurrence of the T790M acquired resistance mutation not only seriously affected the improvement of survival rates, but also impaired the quality of life of NSCLC patients.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative first-, second-, and third-generation EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To prevent the acquired resistance caused by the T790M mutation, several second-generation irreversible EGFR inhibitors have been developed.<a onclick="showRef(event, 'ref11 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13 ref14">(11−14)</a> Afatinib (<b>3</b>) is a typical example, which has been approved by FDA as a new first-line treatment for late stage (metastatic) NSCLC patients with EGFR exon 19 deletions or exon 21 L858R substitution mutations in 2013 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Although afatinib was highly active in vivo in xenograft models driven by EGFR<sup>L858R/T790M</sup>, it did not increase objective response rate in clinical trial of NSCLC patients who have been developed resistance to gefitinib or erlotinib on account of the narrow therapeutic window toward wild-type (WT) EGFR.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Therefore, there is still an unmet clinical need to develop third-generation EGFR TKIs, namely mutant-selective EGFR-TKIs. These inhibitors have potent selectivity for EGFR T790M while sparing wild-type EGFR so the efficacy can be improved and the toxicity associated with the inhibition of WT EGFR protein can be reduced. WZ4002 (<b>4</b>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> with an anilinepyrimidine core, was the first such type of mutant-selective EGFR-TKIs, nevertheless, which did not progress into clinical development. Simultaneously, other two mutant-selective small molecule EGFR inhibitors have been publicly reported that are CO-1686 (<b>5</b>, rociletinib)<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> and AZD9291 (<b>6</b>, osimertinib).<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20,21)</a> These two agents demonstrated good potency and prominent selectivity for EGFR L858R/T790M over WT EGFR (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). Furthermore, according to its significant clinical benefits, FDA has accelerated approved compound <b>6</b> to treat advanced NSCLC patients with EGFR<sup>T790M</sup> acquired resistance mutation, which have progressed on or after prior treatment with other EGFR-targeted therapy.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></div><div class="NLM_p last">Recently, we reported a study of developing a series of mutant-selective EGFR inhibitors with a C4-alkyl-1,4-dihydro-2<i>H</i>-pyrimido[4,5-<i>d</i>][1,3]oxazin-2-ones scaffold.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> By a 3D-comformer based scaffold hopping strategy, we designed a new scaffold of pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione as a starting point to develop a series of novel EGFR<sup>L858R/T790M</sup> selective inhibitors. At the end of a three-round structural optimization, our candidate compound <b>20g</b> displays a favorable selectivity against double-mutant EGFR at both enzymatic and cellular levels. Compound <b>20g</b> also shows a good selectivity profile in in vivo study. Our study provides a new scaffold of mutant-selective EGFR inhibitors by an efficient in silico scheme.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, compounds <b>14a</b>–<b>e</b> were synthesized starting from 1,3-benzendiamine, followed by treatment with di-<i>tert</i>-butyl dicarbonate to give Boc-protected amine (<b>8</b>). Then, compound (<b>8</b>) was reacted with ethyl 2,4-dichloropyrimidine-5-carboxylate to yield ethyl 4-((3-((<i>tert</i>-butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine-5-carboxylate (<b>9</b>) in a good yield. Hydrolysis of the carboxylic ethyl ester group by 1 M NaOH afforded carboxylic acid (<b>10</b>), and the key intermediates (<b>11</b>) were generated with arylamines by replacement of the chloride in the pyrimidine. The amide derivatives (<b>12</b>) were prepared from condensation carboxylic acid derivatives (<b>11</b>) with methylamine hydrochloride. Direct cyclization with 1,1′-carbonyldiimidazole to obtain the ring-closure intermediates (<b>13</b>). Finally, <b>13</b> were deprotected with trifluoroacetic acid in dichloromethane and reacted with acryloyl chloride to produce the target compounds <b>14a</b>–<b>e</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione Derivatives <b>14a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>3</sub>OH, rt, 24 h, 64%; (b) ethyl 2,4-dichloropyrimidine-5-carboxylate, DIPEA, CH<sub>3</sub>CN, reflux, 2 h, 86%; (c) 1 M NaOH, THF, 50 °C, 3 h, 96%; (d) arylamine, CH<sub>3</sub>CN, reflux, overnight, 42–89%; (e) methylamine hydrochloride, HATU, DIPEA, dry DMF, rt, overnight, 31–47%; (f) 1,1′-carbonyldiimidazole, K<sub>2</sub>CO<sub>3</sub>, dry THF, reflux, overnight, 35–42%; (g) trifluoroacetic acid, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 h, 81–90%; (h) acrylyl chloride, NMP/CH<sub>3</sub>CN, 0 °C to rt, overnight, 47–53%.</p></p></figure><div class="NLM_p">To compare the influence of activity, we synthesized a series of final compounds with different substituted alkyl groups at 3-position of pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione moiety (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Commercially available 2,4-dichloro-5-pyrimidinecarbonyl chloride was reacted with ammonium hydroxide to give 2,4-dichloropyrimidine-5-carboxamide (<b>15</b>). Intermediates (<b>17</b>) were generated with Boc-protected amine and appropriate arylamines by replacement of the chloride at the 4- and 2-position of pyrimidine, respectively. Then, the ring-closure compounds (<b>18</b>) were obtained based on the same procedure as described in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>, which further were alkylated with appropriate alkyl halides to afford the N3-alkylated compounds (<b>19</b>).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> At last, the final compounds <b>20a</b>–<b>f</b> were synthesized using the same synthetic methods as described above, and compounds <b>20g</b>–<b>l</b> were prepared by a method similar to that for compound <b>20a</b>.</div><figure id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione Derivatives <b>20a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ammonium hydroxide, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 92%; (b) <i>tert</i>-butyl(3-aminophenyl)carbamate, DIPEA, 2-propanol, 40 °C, 5 h, 84%; (c) arylamine, trifluoroacetic acid, 2-propanol, reflux, overnight, 67%; (d) 1,1′-carbonyldiimidazole, K<sub>2</sub>CO<sub>3</sub>, dry THF, reflux, overnight, 60%; (e) haloalkane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight, 55–61%; (f) trifluoroacetic acid, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h, 78–82%; (g) acrylyl chloride, NMP/CH<sub>3</sub>CN, 0 °C to rt, overnight, 37–49%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10613" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10613" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Scaffold Hopping and Binding Mode Analysis</h3><div class="NLM_p">Through a structure-based design strategy targeting a hydrophobic subpocket induced by a gatekeeper mutant T790M, compound <b>7</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A) was previously identified as a nanomolar irreversible EGFR inhibitor with a double-mutant selective profile (IC<sub>50</sub> against EGFR<sup>L858R/T790M</sup> kinase over EGFR<sup>WT</sup> kinase: 4.7 vs 474 nM, 101-fold selectivity).<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> After superimposing the docked pose of compound <b>7</b> with another double-mutant-selective EGFR inhibitor <b>5</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B), the binding mode of both double-mutant inhibitors share some similar characteristics: (1) The aminopyrimidine moiety of both inhibitors binds to Met793 residue at the hinge region through two hydrogen bonding interactions. (2) The hydrophilic tail on the left-hand side faces toward solvent-exposure area. (3) The warhead, <i>meta</i>-acrylamide group, forms a covalent bond with Cys797. Besides, there are two subpockets induced by gatekeeper mutant T790M (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C). On the basis of the overlaid docked poses of compounds <b>5</b> and <b>7</b>, subpocket 1 (S1) is occupied by the fluorine group in the C5-CF<sub>3</sub> substituent of compound <b>5</b> or the methyl group at N5-position of compound <b>7</b>, respectively. To further improve the selectivity profile, by occupying both mutant-induced subpockets (S1 and S2), compound <b>14a</b> was designed with a novel scaffold: pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione. According to the docked pose of compound <b>14a</b> (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D), the carbonyl group at C4-position occupies the S1 pocket as well, like compounds <b>5</b> and <b>7</b>. And hydrophobic groups with different lengths and volumes at the R<sup>3</sup> position could be introduced to explore the S2 pocket and to strengthen the nonpolar contacts with the gatekeeper mutant Met790.</div><figure id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) The 2D drawings of compound <b>5</b> and <b>7</b>. (B) The overlaid docked poses of <b>5</b> (shown in orange sticks) and <b>7</b> (shown in blue sticks). The gatekeeper, hinge and covalent regions of both wild-type (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J">4G5J</a>) and double-mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) EGFR kinases are displayed in yellow sticks and cyan sticks, respectively. (C) The sliced view of the predicted binding mode of <b>14a</b>. The docked pose of compound <b>14a</b> is in yellow sticks. The key residues Met793 and Met790 are shown in cyan sticks. The rest of the protein is demonstrated in a surface mode (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (D) The 2D interactions of the new scaffold to show strategies of structural modifications. (E) The docked pose of compound <b>20c</b>. The protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) is shown in a blue cartoon, and the key residues are shown in blue sticks. Key H-bond and VDW interactions are measured by distances. (F) The docked pose of compound <b>20f</b>. The compound <b>20f</b> is in orange sticks. The mesh surface is shown to display the shape of the binding site and the S2 pocket. The key residues in the covalent, hinge, and S2-pocket regions of both wild-type (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP">2RGP</a>) and double-mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W2S">3W2S</a>) EGFR kinases are displayed in cyan sticks and green sticks, respectively</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Structure–Activity Relationship</h3><div class="NLM_p"><b>14a</b> inhibited the enzymatic activity against EGFR<sup>L858R/T790M</sup> and EGFR<sup>WT</sup> with IC<sub>50</sub> values of 46 and 180 nM, respectively, and showed nearly 4-fold selectivity for EGFR<sup>L858R/T790M</sup> in comparison with EGFR<sup>WT</sup> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Its in vitro antiproliferation activity were tested by using the sulforhodamine B (SRB) colorimetric assay on H1975 cell lines (expressing EGFR-L858R/T790M) and A431 cell lines (harboring overexpressed EGFR<sup>WT</sup>). However, it exhibited weak antiproliferative effects on both the H1975 and A431 cell lines (>10 μM). Thus, we decided to improve the physical properties of <b>14a</b> by exploring the R<sup>2</sup> position. With a <i>N</i>,<i>N</i>-dimethylpiperidin-4-amine substituent at the R<sup>2</sup> position (compound <b>14d</b>), the predicted cell permeability score was improved from 64.1 (<b>14a</b>) to 80.3 (<b>14d</b>) (the higher value, the better cell permeability, predicted by Qikprop in Maestro software package<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>). As we expected, the enzymatic activity of <b>14d</b> against EGFR kinases and the selectivity between EGFR<sup>L858R/T790M</sup> and EGFR<sup>WT</sup> remain the same level as <b>14a</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Besides, compound <b>14d</b> displayed potent inhibitory activity against H1975 cell line (230 nM) and showed selectivity against the H1975 over the A431 cell lines (approximately 17-fold). As a contrast, we also synthesized compound <b>14e</b> with no modification on R<sup>1</sup> and R<sup>2</sup>. As expected, <b>14e</b> lost the selectivity between EGFR<sup>L858R/T790M</sup> and EGFR<sup>WT</sup> and showed weak antiproliferative effects on both the H1975 and A431 cell lines (>9 μM). The results once again verify the importance of the hydrophilic tail on the left-hand side. Because compound <b>14d</b> showed better inhibitory activity at both enzymatic and cellular levels and acceptable aqueous solubility (531 μg/mL), it was selected as a new starting point for the next-round structure modifications.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. In Vitro EGFR Inhibitory Activity and Antiproliferation Activity of Compounds <b>14a</b>–<b>e</b><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0008.gif" alt="" id="GRAPHIC-d7e946-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0009.gif" alt="" id="gr8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Kinase activity assays were examined by using the ELISA-based EGFR-TK assay. The antiproliferation activity of the compounds were employed by using the sulforhodamine B (SRB) colorimetric assay. Data are averages of at least three independent determinations and reported as the means ± SDs (standard deviations).</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Aqueous solubility of these derivatives was examined by using UV–visible spectrophotometer in PBS buffer (0.1 M, pH 7.4).</p></div></div><div></div></div><div class="NLM_p">On the basis of the strategy we described in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>D, probing the S2 pocket is one of the most important structure-based optimizations to improve the selectivity against double mutants over wild type. Considering the feasibility of synthesis, hydrophobic groups with varied length and volume were introduced at R<sup>3</sup> position (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Thus, compounds <b>20a</b>–<b>f</b> were synthesized (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). When varying the substituted group at R<sup>3</sup> position from methyl, ethyl, propyl, to isopropyl (compounds <b>14d</b>, <b>20a</b>–<b>c</b>), the enzymatic inhibition against double-mutant EGFR also boosted correspondingly with the increase of group length and volume. For compounds <b>20b</b> and <b>20c</b>, their values of IC<sub>50</sub> against double-mutant EGFR reach the subnanomolar range (0.4 and 0.8 nM, respectively, <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). On the basis of the docking simulation (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>E), the hydrophobic groups at R<sup>3</sup> position is able to occupy the T790M mutant induced S2 pocket as well as strengthen van der Waals (VDWs) contacts with gatekeeper Met790. Compared with the positive control compound <b>5</b>, all three compounds (<b>20a</b>–<b>c</b>) showed a double-mutant preferred selectivity (14-fold vs 44-, 33-, and 25-fold), but the longer and bulkier substituents at R<sup>3</sup> position (compounds <b>20d</b>–<b>f</b>) keep potent inhibitory activity against double-mutant EGFR and these structural modifications also increase the inhibition against wild-type EGFR, resulting in complete loss of double-mutant selective profile (0.6-, 0.7-, 2.7-fold, respectively). There are many structures that show the flexibility of S2 pocket to accommodate a wide range of hydrophobic moieties in both EGFR double mutant and wild-type structures.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> According to our docking simulations, compound <b>20f</b> is able to be docked into both double-mutant and wild-type EGFR structures with a wide open S2 pocket (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf" class="ext-link">Figure S1</a>). On the basis of the docked pose of <b>20f</b> with double-mutant EGFR, we believe that the energy gain from occupying at S2 pocket with bulkier group compensates the steric strain (1.9 Å: the distance in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F shows unfavorable VDW interactions) between the carbonyl group at C4-position and wild-type gatekeeper Thr790. Thus, compounds with longer and bulkier substituents at R<sup>3</sup> position regain inhibitory activity against wild-type EGFR. At the second-round optimization, compounds <b>20a</b>–<b>c</b> also showed a better selectivity against H1975 cell lines over A431 cell lines than that of compounds <b>20d</b>–<b>f</b> (12-, 11-, and 4-fold, respectively). This trend is in consistent with that at the enzymatic level.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. In Vitro EGFR Inhibitory Activity and Antiproliferation Activity of Compounds <b>20a</b>–<b>l</b><a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0010.gif" alt="" id="GRAPHIC-d7e1091-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0011.gif" alt="" id="gr9" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Data are averages of at least three independent determinations and reported as the means ± SDs (standard deviations).</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Not determined.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Aqueous solubility of these derivatives was examined by using UV–visible spectrophotometer in PBS buffer (0.1 M, pH 7.4).</p></div></div><div></div></div><div class="NLM_p last">At the third round, we moved forward with the most selective one at cellular level (<b>20c</b>) for further structural optimizations. Previously, some literature has also reported modification of the left-hand side chain of the compounds to discover active candidates.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29−31)</a> Inspired by that, we synthesized a set of compounds (compounds <b>20g</b>–<b>l</b>) that possess different left-hand side chains on the basis of <b>20c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The data revealed that compounds <b>20h</b> and <b>20j</b>–<b>l</b> displayed varying degrees selectivity losses in EGFR enzymatic inhibitory activity compared with <b>20c</b>. Encouragingly, compounds <b>20g</b> and <b>20i</b> demonstrated more potent selectivity for double-mutant EGFR enzyme (263-fold and 34-fold, respectively) and increase of aqueous solubility (262 and 280 μg/mL, respectively) than <b>20c</b>. Especially <b>20g</b>, which showed 263-fold selectivity between the EGFR<sup>L858R/T790M</sup> and the EGFR<sup>WT</sup>, and showed more potent inhibitory activity and selectivity than the positive control compound <b>5</b>. Consistent with their enzyme inhibitory activity, these compounds also showed different results in antiproliferation assays. Compounds <b>20g</b>–<b>i</b> were roughly equipotent to <b>20c</b> for the H1975 cell lines but resulted in varying degrees drops of selectivity for A431 cells, especially <b>20h</b> and <b>20i</b>, and <b>20j</b>–<b>l</b> exhibited diminished antiproliferation activity for H1975 cells and increased antiproliferation efficiency for A431 cells as compared to <b>20c</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>).</div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Inhibitory Effects of EGFR and Downstream Signaling Transduction</h3><div class="NLM_p">The selective inhibition of the representative compound <b>20g</b> for the phosphorylation of EGFR and the downstream signaling transduction was further confirmed by using the Western blot analysis (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). In H1975 cells, <b>20g</b> inhibited the phosphorylation of EGFR<sup>L858R/T790M</sup> at the concentration as low as 1 nM and potently inhibited EGFR phosphorylation and downstream molecules AKT phosphorylation at 100 nM, which even showed more potent inhibitory activity relative to compound <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). In A431cells, <b>20g</b> moderately inhibited the phosphorylation of EGFR<sup>WT</sup> even at 100 nM (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). The results clearly showed that compound <b>20g</b> more potently inhibited the phosphorylation of EGFR and downstream signaling transduction (p-AKT) in cellular level, further suggesting <b>20g</b> was a potent and selective EGFR<sup>L858R/T790M</sup> inhibitor.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitory effects of compound <b>20g</b> for EGFR and downstream signaling transduction in H1975 cells (A) and A431 cells (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Target Duration of Action of Compound <b>20g</b> in Vitro</h3><div class="NLM_p">To get an insight into the duration of target inhibition in vitro, we performed a washout experiment. Compound <b>20g</b> was washed out after incubation for 2 h in H1975 cells. Then phosphorylation of target at different time points was detected by Western blot. As shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A, inhibition of target EGFR<sup>L858R/T790M</sup> activation can last for 24 h at least, and inhibition of the signaling protein ERK activation can also last for more than 12 h. Furthermore, the target duration was similar to that of control compound <b>6</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Target duration in vitro. NCI-H1975 cells were treated with <b>20g</b> (A) or compound <b>6</b> (B) for 2 h, then washed with PBS for three times. Target inhibition at different time points was detected by Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> DMPK Properties of Compound <b>20g</b></h3><div class="NLM_p">In the permeability properties assay, compound <b>20g</b> showed modest permeability in the MDCK II cells (<i>P</i><sub>app</sub>,<sub>A→B</sub> of 1.5 × 10<sup>–6</sup> cm/s, and <i>P</i><sub>app</sub> ratio of 9.1 at 2 μM). We then examined the in vitro metabolic stability of compound <b>20g</b> with human and mouse liver microsomes. At the assay concentration of 0.1 μM, the results demonstrated that <b>20g</b> exhibited acceptable microsomal stability with half-life (<i>T</i><sub>1/2</sub>) of 85.4 min (human liver microsomes) and 46.1 min (mouse liver microsomes), and MF% of 44.3 and 49.4, respectively (Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf" class="ext-link">Table S1</a>). In addition, <b>20g</b> showed weak cytochrome P450 (CYP450) inhibition against five major human CYP450 enzymes (1A2, 2C9, 2C19, and 2D6 IC<sub>50</sub> > 50 μM; 3A4 IC<sub>50</sub> = 23.9 μM). We also examined the preliminary in vivo pharmacokinetic properties of compound <b>20g</b> in mice following intravenous (IV) and oral administration. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>, <b>20g</b> demonstrated a reasonable area under the curve (AUC<sub>0–∞</sub>) value of 658 ng·h/mL, moderate half-life (<i>T</i><sub>1/2</sub> = 1.1 h), and oral bioavailability (<i>F</i> = 35%) during the oral dose of 10 mg/kg. The results indicate that it is meaningful to further evaluate the preliminary in vivo antitumor efficacy studies of compound <b>20g</b>.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Mouse Pharmacokinetics Parameters for Compound <b>20g</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (route)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–<i>t</i>)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>(0–∞)</sub> (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub><i><i>z</i></i></sub> (mL/kg)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL/h/kg)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1 mg/kg (IV)</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.1</td><td class="colsep0 rowsep0" align="char" char=".">311</td><td class="colsep0 rowsep0" align="char" char=".">181</td><td class="colsep0 rowsep0" align="char" char=".">186</td><td class="colsep0 rowsep0" align="char" char=".">4530</td><td class="colsep0 rowsep0" align="char" char=".">5370</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10 mg/kg (PO)</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">271</td><td class="colsep0 rowsep0" align="char" char=".">650</td><td class="colsep0 rowsep0" align="char" char=".">658</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">35</td></tr></tbody></table></div></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vivo Antitumor Efficiency Study</h3><div class="NLM_p">On the basis of its outstanding in vitro inhibitory activity, we selected compound <b>20g</b> to further evaluate its preliminary in vivo antitumor efficacy in H1975 and A431 xenograft mouse models (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). In this study, 4–6 week-old mice (<i>n</i> = 6/group) in treatment group were dosed orally once daily with <b>20g</b> at 50 mg/kg for 14 days. As shown in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A, compared with the vehicle group, <b>20g</b> significantly inhibited the tumor growth (TGI = 73%, <i>p</i> < 0.001) during the 14 day period in H1975 xenograft mouse mode. However, <b>20g</b> exhibited much less potent tumor growth inhibition (TGI = 37%, <i>p</i> < 0.05) in the A431 xenograft mouse model (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B). Besides, during the experiment, no significant body weight loss, mortality, and obvious side effects were observed (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C,D), indicating that compound <b>20g</b> was well-tolerated at this dose.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Preliminary in vivo antitumor efficiency study of compound <b>20g</b> (50 mg/kg/day) against H1975 and A431 NSCLC xenograft mouse models. (A) H1975 xenograft mouse model (<i>n</i> = 6) tumor volumes and (C) body weights. (B) A431 xenograft mouse model (<i>n</i> = 6) tumor volumes and (D) body weights were recorded every 2–3 days. All values expressed as mean ± SEM (*) <i>p</i> < 0.05 or (***) <i>p</i> < 0.001 (Student’s <i>t</i> test) vs the vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Through a 3D conformer based scaffold hopping protocol based on previously reported mutant-selective EGFR inhibitors, we designed and synthesized a series of pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione derivatives as novel potent and selective EGFR<sup>L858R/T790M</sup> inhibitors. For three compounds (<b>20b</b>, <b>20c</b>, and <b>20g</b>) in this series, our design strategy to occupy S2 pocket boosts the inhibitions against double-mutant EGFR and brings the IC<sub>50</sub> to a subnanomolar level. After three rounds of SAR exploration, one of the most promising compounds <b>20g</b> shows a favorable selectivity at both in vitro and in vivo levels, indicating that compound <b>20g</b> might be used as a promising drug candidate to overcome EGFR<sup>L858R/T790M</sup> drug-resistance mutation. Further evaluation for the candidate compound is still ongoing and will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47030" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47030" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Molecular Modeling</h3><div class="NLM_p">The X-ray structures (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J">4G5J</a>) were downloaded from the Protein Data Bank (PDB, <a href="http://www.pdb.org" class="extLink">http://www.pdb.org</a>). The protocol of comparative docking study was reported in our previous publications:<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> First, compounds <b>5</b> and <b>7</b> was docked into the EGFR<sup>T790M</sup> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) as reversible inhibitors using Glide<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (version 5.5) in extra precision (XP) mode with default settings. Then, the covalent bond between the Cys797 and the electrophilic group was formed by the build panel in Maestro.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Finally, to fix the bond lengths and eliminate steric clashed, the inhibitor–kinase covalent complex was minimized in water solvent using MacroModel application with a flexible ligand and a restrained protein.</div><div class="NLM_p">The scaffold hopping was conducted by an in-house software, SHAFTS.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The query molecule was the docked pose of compound <b>7</b> obtained from the above docking study. The aligned pose of compound <b>20c</b> (similarity score was 1.2875) was generated by a fast 3D-similarity calculation in SHAFTS.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Then, the covalent bond was formed and complexes minimized with MacroModel application with the same settings as described above.</div><div class="NLM_p last">For getting docked poses of compound <b>20f</b> with wild-type and double-mutant EGFRs. Two structures (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP">2RGP</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W2S">3W2S</a>) were prepared in Maestro and aligned to the structure with PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>. Compound <b>20f</b> (similarity score is 1.4038) was aligned to the docked pose of compound <b>7</b> by SHAFTS then manually formed the covalent bond and minimized in MacroModel.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Reagents and General Methods</h3><div class="NLM_p">All chemical reagents and solvents used in experiments were purchased from commercial suppliers and used without further purification. Silica gel (300–400 mesh) used for column chromatography and thin-layer chromatography (TLC) used to monitor progress of the reaction were purchased from Qingdao Haiyang Chemical Co., Ltd. <sup>1</sup>H and <sup>13</sup>C NMR spectra were performed on the Bruker spectrometer (AV-400) at 400 and 100 MHz, respectively. The low-resolution mass spectra (LC-MS) were measured using Agilent 6120 LC-MS. The high-resolution mass spectra (HRMS, Waters LCT Premier XE TOF) were measured at the Institute of Fine Chemistry of ECUST. Melting points were determined with the digital melting point apparatus (WRS-1B). The purity of final compounds were analyzed by HPLC (Hewlett-Packard 1100), with the purity of all compounds being over than 95%. The HPLC instrument was equipped with a photodiode array detector using a Zorbax RP-18 column (5 μm, 4.6 mm × 250 mm, reverse phase column). The mobile phases A and B were acetonitrile and the solution of 10 mM ammonium acetate in purified water (pH = 6.0), respectively.</div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> <i>tert</i>-Butyl(3-aminophenyl)carbamate (<b>8</b>)</h4><div class="NLM_p last">To a mixture of 1,3-phenylenediamine (10.800 g, 100 mmol), Et<sub>3</sub>N (10.100 g, 100 mmol) in methanol (150 mL) was added Boc<sub>2</sub>O (21.800 g, 100 mmol) at 0 °C. The reaction solution was stirred for 24 h at room temperature. Then the solution was concentrated with a rotary evaporator. The crude product was purified by silica gel chromatography (petroleum ether/ethyl acetate = 4:1, v/v) to obtain the title compound 2 as white powder (13.310 g, 64%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.03 (t, <i>J</i> = 8.0 Hz, 1H), 6.96 (s, 1H), 6.55 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 1.2 Hz, 1H), 6.43 (s, 1H), 6.36 (dd, <i>J</i> = 8.0 Hz, <i>J</i> = 1.6 Hz, 1H), 3.54 (s, 2H), 1.51 (s, 9H). LC-MS: <i>m</i>/<i>z</i>: 209.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> Ethyl 4-((3-((<i>tert</i>-Butoxycarbonyl)amino)phenyl)amino)-2-chloropyrimidine-5-carboxylate (<b>9</b>)</h4><div class="NLM_p last">A mixture of ethyl-2,4-dichloropyrimidine-5-carboxylate (2.210 g, 10 mmol), compound <b>8</b> (2.080 g, 10 mmol), and DIPEA (1.935 g, 15 mmol) in CH<sub>3</sub>CN (40 mL) was heated with reflux for 2 h. After cooling to room temperature, the white solid was collected by filtration and washed with CH<sub>3</sub>CN to give the product <b>9</b> (3.371 g, 86%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 9.50 (s, 1H), 8.80 (s, 1H), 7.70 (s, 1H), 7.35 (d, <i>J</i> = 7.6 Hz, 1H), 7.29 (t, <i>J</i> = 8.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.4 Hz, 1H), 4.39 (q, <i>J</i> = 7.2 Hz, 2H), 1.49 (s, 9H), 1.36 (t, <i>J</i> = 7.2 Hz, 3H). LC-MS: <i>m</i>/<i>z</i>: 393.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 4-((3-((<i>tert</i>-Butoxycarbonyl)Amino)phenyl)amino)-2-chloropyrimidine-5-carboxylic Acid (<b>10</b>)</h4><div class="NLM_p last">A mixture of compound <b>9</b> (3.136 g, 8 mmol) in THF and 1 M NaOH (8 mL) was heated at 50 °C for 3 h. After cooling to room temperature, the solution was acidified with 1 M HCl to give a white solid, which was collected by filtration and washed with THF and water to give the title compound <b>10</b> (2.796 g, 96%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.84 (s, 1H), 9.49 (s, 1H), 8.76 (s, 1H), 7.67 (s, 1H), 7.40 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (t, <i>J</i> = 8.0 Hz, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 1H), 1.49 (s, 9H). LC-MS: <i>m</i>/<i>z</i>: 365.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 4-((3-((<i>tert</i>-Butoxycarbonyl)Amino)phenyl)amino)-2-(phenylamino)pyrimidine-5-carboxylic Acid (<b>11</b>)</h4><div class="NLM_p last">To a solution of compound <b>10</b> (2.184 g, 6 mmol) in CH<sub>3</sub>CN (40 mL) was added aniline (0.558 g, 6 mmol), and the mixture was heated with reflux for 12 h. After cooling to room temperature, the residue was collected by filtration and washed with CH<sub>3</sub>CN to give the product <b>11</b> as a white solid (2.249 g, 89%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.44 (s, 1H), 9.82 (s, 1H), 9.36 (s, 1H), 8.70 (s, 1H), 7.69 (d, <i>J</i> = 8.0 Hz, 2H), 7.63 (s, 1H), 7.43 (s, 1H), 7.26–7.21 (m, 4H), 6.98 (t, <i>J</i> = 6.8 Hz, 1H), 1.47 (s, 9H). HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>24</sub>N<sub>5</sub>O<sub>4</sub> 422.1828, found 422.1823.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> <i>tert</i>-Butyl(3-((5-(methylcarbamoyl)-2-(phenylamino)pyrimidin-4-yl)amino)phenyl)carbamate (<b>12</b>)</h4><div class="NLM_p last">To a solution of <b>11</b> (1.263 g, 3 mmol) and DIPEA (0.774 g, 6 mmol) in dry DMF (15 mL) was added HATU (1.368 g, 3.6 mmol). After stirring for 1 h at room temperature, methylamine hydrochloride (0.306 g, 4.5 mmol) was added and stirred overnight. The reaction mixture was poured into ice–water, and the resulting solid was collected by filtration, washed with water and recrystallized from EtOH to give the product <b>12</b> (0.612 g, 47%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.33 (s, 1H), 9.59 (s, 1H), 9.31 (s, 1H), 8.64 (s, 1H), 8.50 (d, <i>J</i> = 4.8 Hz, 1H), 7.69 (d, <i>J</i> = 7.6 Hz, 2H), 7.62 (s, 1H), 7.50–7.48 (m, 1H), 7.23 (t, <i>J</i> = 7.6 Hz, 2H), 7.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 6.96 (t, <i>J</i> = 7.2 Hz, 1H), 2.79 (d, <i>J</i> = 4.4 Hz, 3H), 1.47 (s, 9H). LC-MS: <i>m</i>/<i>z</i>: 435.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> <i>tert</i>-Butyl(3-(3-methyl-2,4-dioxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)carbamate (<b>13</b>)</h4><div class="NLM_p last">To a solution of <b>12</b> (0.434 g, 1 mmol), K<sub>2</sub>CO<sub>3</sub> (0.276 g, 2 mmol) in dry THF (10 mL) was added 1,1′-carbonyldiimidazole (0.324 g, 2 mmol). The reaction mixture was heated with reflux overnight. After cooling to room temperature, the reaction mixture was poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 1:2, v/v) to give the product <b>13</b> as a white solid (0.193 g, 42%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.62 (s, 1H), 8.92 (s, 1H), 7.66 (s, 1H), 7.52 (d, <i>J</i> = 8.0 Hz, 1H), 7.45 (t, <i>J</i> = 8.0 Hz, 1H), 7.36–7.32 (m, 2H), 7.03 (d, <i>J</i> = 8.0 Hz, 3H), 6.91 (d, <i>J</i> = 7.2 Hz, 1H), 3.30 (s, 3H), 1.45 (s, 9H). HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>24</sub>H<sub>25</sub>N<sub>6</sub>O<sub>4</sub> 461.1937, found 461.1939.</div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> <i>N</i>-(3-(3-Methyl-2,4-dioxo-7-(phenylamino)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>14e</b>)</h4><div class="NLM_p">To a solution of <b>13</b> (0.190 g, 0.41 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 mL) was added trifluoroacetic acid (1 mL). The mixture was stirred for 4 h at room temperature. The reaction solution was neutralized with saturated aqueous NaHCO<sub>3</sub>, and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to obtain a white solid (0.136 g, 90%), which was used in the next reaction without further purification.</div><div class="NLM_p">To a solution of 1-(3-aminophenyl)-3-methyl-7-(phenylamino)pyrimido[4,5-<i>d</i>] pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (0.136 g, 0.38 mmol) in NMP (1.5 mL) was added acryloyl chloride (37 μL, 0.46 mmol) dissolved in CH<sub>3</sub>CN (0.5 mL) at 0 °C. The reaction solution was stirred overnight at room temperature. The mixture was poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 15 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (petroleum ether/ethyl acetate = 1:1.5, v/v) to give the product <b>14e</b> as a white solid (0.083 g, 53%); mp 290.3–291.2 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.93 (s, 1H), 7.82 (d, <i>J</i> = 3.2 Hz, 1H), 7.80 (s, 1H), 7.53 (t, <i>J</i> = 8.0 Hz, 1H), 7.33–7.29 (m, 2H), 7.15 (d, <i>J</i> = 7.6 Hz, 1H), 7.02–6.96 (m, 2H), 6.89 (t, <i>J</i> = 6.0 Hz, 1H), 6.44 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 10.4 Hz, 1H), 6.25 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 5.76 (dd, <i>J</i> = 10.4 Hz, <i>J</i> = 2.0 Hz, 1H), 3.30 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.24, 160.11, 158.97, 157.87, 150.86, 139.90, 138.91, 136.19, 131.61, 129.45, 128.11, 127.22, 124.30, 122.53, 120.07, 119.26, 119.07, 27.57. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>22</sub>H<sub>19</sub>N<sub>6</sub>O<sub>3</sub> 415.1519, found 415.1512. HPLC purity: 97.66%, retention time = 10.68 min.</div><div class="NLM_p last">The following compounds <b>14a</b>–<b>d</b> were prepared by a method similar to that for the synthesis of compound <b>14e</b>.</div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> <i>N</i>-(3-(7-((4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>14a</b>)</h4><div class="NLM_p last">Yellow solid (yield 49%); mp 228.5–229.8 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.34 (s, 1H), 8.83 (s, 1H), 8.59 (s, 1H), 7.86 (s, 1H), 7.69 (s, 1H), 7.48 (t, <i>J</i> = 8.4 Hz, 1H), 7.18 (d, <i>J</i> = 8.8 Hz, 1H), 7.09 (d, <i>J</i> = 8.0 Hz, 1H), 6.55 (s, 1H), 6.45 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 10.4 Hz, 1H), 6.26 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 5.99 (s, 1H), 5.77 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.2 Hz, 1H), 3.76 (s, 3H), 3.58–3.54 (m, 4H), 3.28 (s, 3H), 3.05–2.99 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 168.19, 163.21, 160.10, 157.83, 139.73, 135.99, 131.67, 129.33, 127.18, 49.15, 48.76, 45.42, 40.60, 27.54, 21.16. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>31</sub>N<sub>8</sub>O<sub>5</sub> 571.2417, found 571.2417. HPLC purity: 97.63%, retention time = 9.50 min.</div></div><div id="sec5_2_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> <i>N</i>-(3-(7-((2-Methoxy-4-morpholinophenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>14b</b>)</h4><div class="NLM_p last">Yellow solid (yield 51%); mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 8.80 (s, 1H), 8.44 (s, 1H), 8.03 (s, 1H), 7.86 (d, <i>J</i> = 8.0 Hz, 1H), 7.69 (t, <i>J</i> = 2.0 Hz, 1H), 7.52 (t, <i>J</i> = 8.4 Hz, 1H), 7.32 (d, <i>J</i> = 8.8 Hz, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.57 (d, <i>J</i> = 2.0 Hz, 1H), 6.45 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 10.0 Hz, 1H), 6.27 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 2.0 Hz, 1H), 5.77 (dd, <i>J</i> = 10.4 Hz, <i>J</i> = 2.0 Hz, 1H), 3.77 (s, 3H), 3.58–3.54 (m, 4H), 3.06–2.99 (m, 4H), 2.05 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.23, 160.09, 158.87, 157.82, 150.86, 149.81, 148.06, 139.74, 135.98, 131.65, 129.34, 127.19, 124.18, 121.08, 120.00, 119.12, 105.61, 99.65, 99.15, 66.03, 55.64, 48.78, 27.54. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>28</sub>N<sub>7</sub>O<sub>5</sub> 528.1995, found 528.1993. HPLC purity: 96.86%, retention time = 10.73 min.</div></div><div id="sec5_2_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> <i>N</i>-(3-(7-((2-Methoxy-4-thiomorpholinophenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>14c</b>)</h4><div class="NLM_p last">Yellow solid (yield 52%); mp 246.0–247.1 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.35 (s, 1H), 8.84 (s, 1H), 8.60 (s, 1H), 8.85 (s, 1H), 7.70 (s, 1H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 8.4 Hz, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.45 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 10.0 Hz, 1H), 6.27 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 2.0 Hz, 1H), 5.97–5.95 (m, 1H), 5.77 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.6 Hz, 1H), 3.75 (s, 3H), 3.42–3.39 (m, 4H), 3.28 (s, 3H), 2.66–2.63 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.24, 160.08, 158.90, 157.81, 150.86, 149.99, 139.76, 135.99, 131.63, 129.33, 127.22, 124.19, 121.32, 120.01, 119.10, 106.85, 100.43, 99.63, 55.65, 51.46, 27.54, 25.62. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>27</sub>H<sub>28</sub>N<sub>7</sub>O<sub>4</sub>S 546.1923, found 546.1924. HPLC purity: 95.21%, retention time = 12.49 min.</div></div><div id="sec5_2_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> <i>N</i>-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-methyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>14d</b>)</h4><div class="NLM_p last">Yellow solid (yield 47%); mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.36 (s, 1H), 8.83 (s, 1H), 8.54 (s, 1H), 7.88–7.86 (m, 1H), 7.70 (s, 1H),7.47 (t, <i>J</i> = 8.0 Hz, 1H), 7.16 (d, <i>J</i> = 8.4 Hz, 1H), 7.08 (d, <i>J</i> = 7.6 Hz, 1H), 6.50–6.43 (m, 2H), 6.26 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.6 Hz, 1H), 5.98–5.96 (m, 1H), 5.76 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.2 Hz, 1H), 3.75 (s, 3H), 3.59–3.58 (m, 2H), 3.28 (s, 3H), 2.60–2.55 (m, 2H), 2.22 (s, 6H), 1.81 (d, <i>J</i> = 7.6 Hz, 2H), 1.47–1.40 (m, 2H). HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>35</sub>N<sub>8</sub>O<sub>4</sub> 571.2781, found 571.2780. HPLC purity: 97.96%, retention time = 11.35 min.</div></div><div id="sec5_2_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2,4-Dichloropyrimidine-5-carboxamide (<b>15</b>)</h4><div class="NLM_p last">To a solution of 2,4-dichloropyrimidine-5-carbonyl chloride (4.220 g, 20 mmol) in dichloromethane (15 mL) was added ammonium hydroxide (1.400 g, 40 mmol) at 0 °C. The reaction mixture was stirred for 2 h at 0 °C, and the mixture was poured into ice–water. The resulting solid was collected by filtration and washed with water to give the product <b>15</b> as a white solid (3.510 g, 92%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.91 (s, 1H), 8.20 (s, 1H), 8.08 (s, 1H).</div></div><div id="sec5_2_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> <i>tert</i>-Butyl(3-((5-carbamoyl-2-chloropyrimidin-4-yl)amino)phenyl)carbamate (<b>16</b>)</h4><div class="NLM_p last">A mixture of compound <b>15</b> (3.438 g, 18 mmol), DIPEA (3.483 g, 27 mmol), and compound <b>8</b> (3.744 g, 18 mmol) in 2-propanol (50 mL) was heated at 40 °C for 5 h. After cooling to room temperature, the white solid was collected by filtration and washed with 2-propanol to give the product <b>16</b> (5.480 g, 84%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (s, 1H), 9.49 (s, 1H), 8.78 (s, 1H), 8.47 (s, 1H), 8.00 (s, 1H), 7.64 (s, 1H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 7.27 (t, <i>J</i> = 8.0 Hz, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 1H), 1.48 (s, 9H). LC-MS: <i>m</i>/<i>z</i>: 364.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>tert</i>-Butyl(3-((5-carbamoyl-2-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl) amino)pyrimidin-4-yl)amino)phenyl)carbamate (<b>17</b>)</h4><div class="NLM_p last">To a mixture of compound <b>16</b> (5.082 g, 14 mmol) and trifluoroacetic acid (1.550 mL, 21 mmol) in 2-propanol (100 mL) was added 1-(4-amino-3-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethylpiperidin-4-amine (4.183 g, 16.8 mmol). The reaction solution was heated with reflux overnight. After cooling to room temperature, the solution was concentrated with a rotary evaporator and neutralized with saturated aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane/methanol = 15:1, v/v) to give the product 11 (5.450 g, 67%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.46 (s, 1H), 9.34 (s, 1H), 8.65 (s, 1H), 8.24 (s, 1H), 8.08 (s, 1H), 7.52 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (d, <i>J</i> = 7.6 Hz, 1H), 7.37 (s, 1H), 7.12–7.07 (m, 2H), 6.62 (d, <i>J</i> = 1.6 Hz, 1H), 6.45 (d, <i>J</i> = 8.4 Hz, 1H), 3.77 (s, 3H), 3.70 (d, <i>J</i> = 12.0 Hz, 2H), 2.66 (t, <i>J</i> = 11.2 Hz, 2H), 2.20 (s, 6H), 1.84 (d, <i>J</i> = 12.0 Hz, 2H), 1.54–1.49 (m, 2H), 1.47 (s, 9H). LC-MS: <i>m</i>/<i>z</i>: 577.4 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>tert</i>-Butyl(3-(7-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)carbamate (<b>18</b>)</h4><div class="NLM_p last">A mixture of compound <b>17</b> (5.184 g, 9 mmol), K<sub>2</sub>CO<sub>3</sub> (1.863 g, 13.5 mmol), and 1,1′-carbonyldiimidazole (2.916 g, 18 mmol) in dry THF (40 mL) was heated with reflux overnight. After cooling to room temperature, the solution was added ice–water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane/methanol = 12:1, v/v) to give the product <b>18</b> (3.289 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.55 (s, 1H), 9.59 (s, 1H), 8.77 (s, 1H), 8.54 (s, 1H), 7.53 (s, 2H), 7.38 (t, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 6.8 Hz, 1H), 6.96 (d, <i>J</i> = 7.2 Hz, 1H), 6.50 (s, 1H), 6.02–5.99 (m, 1H), 3.76 (s, 3H), 3.61–3.59 (m, 2H), 2.62–2.57 (m, 2H), 2.19 (s, 6H), 1.82 (d, <i>J</i> = 12.0 Hz, 2H), 1.51–1.48 (m, 2H), 1.46 (s, 9H). LC-MS: <i>m</i>/<i>z</i>: 603.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>tert</i>-Butyl(3-(7-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-ethyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)carbamate (<b>19</b>)</h4><div class="NLM_p last">To a mixture of compound <b>18</b> (0.602 g, 1 mmol) and Cs<sub>2</sub>CO<sub>3</sub> (0.489 g, 1.5 mmol) in DMF (5 mL) was added iodoethane (95 μL, 1.2 mmol). The mixture was stirred at room temperature overnight. The solution was added ice–water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane/methanol = 13:1, v/v) to give the title compound <b>19</b> (0.378 g, 60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.60 (s, 1H), 8.83 (s, 1H), 8.58 (s, 1H), 7.57 (s, 1H), 7.53–7.51 (m, 1H), 7.39 (t, <i>J</i> = 7.6 Hz, 1H), 7.18 (d, <i>J</i> = 7.6 Hz, 1H), 6.97 (d, <i>J</i> = 7.2 Hz, 1H), 6.51 (s, 1H), 6.03–6.01 (m, 1H), 3.93 (q, <i>J</i> = 6.4 Hz, 2H), 3.76 (s, 3H), 3.63–3.60 (m, 2H), 2.63–2.58 (m, 2H), 2.24 (s, 6H), 1.83 (d, <i>J</i> = 12.0 Hz, 2H), 1.52–1.47 (m, 2H), 1.46 (s, 9H), 1.17 (t, <i>J</i> = 6.8 Hz, 3H). LC-MS: <i>m</i>/<i>z</i>: 631.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_2_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>N</i>-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-ethyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20a</b>)</h4><div class="NLM_p">To a solution of compound <b>19</b> (0.348 g, 0.55 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) was added trifluoroacetic acid (1.5 mL). The mixture was stirred for 5 h at room temperature. The reaction solution was neutralized with saturated aqueous NaHCO<sub>3</sub> and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 30 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo to obtain a yellow solid (0.241 g, 82%), which was used in the next reaction without further purification.</div><div class="NLM_p">To a solution of 1-(3-aminophenyl)-7-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-ethylpyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione (0.220 g, 0.4 mmol) in NMP (1.5 mL) was added acryloyl chloride (42 μL, 0.5 mmol) dissolved in CH<sub>3</sub>CN (0.5 mL) at 0 °C. The reaction solution was stirred overnight at room temperature. The mixture was poured into water and extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 20 mL). The organic layer was washed with saturated aqueous NaCl, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated in vacuo. The residue was purified by silica gel chromatography (dichloromethane/methanol = 12:1, v/v) to give the title product <b>20a</b> as a yellow solid (0.116 g, 49%); mp 212.1–213.6 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 10.56 (s, 1H), 8.84 (s, 1H), 8.62 (s, 1H), 7.92–7.90 (m, 1H), 7.71 (s, 1H),7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.17 (d, <i>J</i> = 6.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.2 Hz, 1H), 6.55–6.49 (m, 2H), 6.28 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.6 Hz, 1H), 6.00 (s, 1H), 5.78 (dd, <i>J</i> = 11.2 Hz, <i>J</i> = 1.2 Hz, 1H), 3.94 (q, <i>J</i> = 6.4 Hz, 2H), 3.76 (s, 3H), 3.72–3.68 (m, 2H), 2.73 (s, 6H), 2.60 (t, <i>J</i> = 8.0 Hz, 1H), 2.63–2.58 (m, 2H), 2.09 (d, <i>J</i> = 11.2 Hz, 2H), 1.72–1.68 (m, 2H), 1.18 (t, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>31</sub>H<sub>37</sub>N<sub>8</sub>O<sub>4</sub> 585.2938, found 585.2928. HPLC purity: 96.26%, retention time = 9.95 min.</div><div class="NLM_p last">The following compounds <b>20b</b>–<b>l</b> were prepared by a synthesis route similar to that for compound <b>20a</b>.</div></div><div id="sec5_2_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>N</i>-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3-propyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20b</b>)</h4><div class="NLM_p last">Yellow solid (yield 39%); mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 8.84 (s, 1H), 8.63 (s, 1H), 7.92 (s, 1H), 7.69 (s, 1H), 7.49 (t, <i>J</i> = 8.0 Hz, 1H), 7.19 (d, <i>J</i> = 6.8 Hz, 1H), 7.10 (d, <i>J</i> = 7.8 Hz, 1H), 6.54–6.48 (m, 2H), 6.28 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.2 Hz, 1H), 6.00 (s, 1H), 5.78 (dd, <i>J</i> = 10.4 Hz, <i>J</i> = 1.6 Hz, 1H), 3.86 (t, <i>J</i> = 6.8 Hz, 2H), 3.76 (s, 3H), 3.72–3.69 (m, 2H), 3.26–3.21 (m, 1H), 2.72 (s, 6H), 2.62–2.57 (m, 2H), 2.07 (d, <i>J</i> = 11.2 Hz, 2H), 1.70–1.67 (m, 2H), 1.65–1.60 (m, 2H), 0.90 (t, <i>J</i> = 7.2 Hz, 3H). HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>32</sub>H<sub>39</sub>N<sub>8</sub>O<sub>4</sub> 599.3094, found 599.3099. HPLC purity: 97.85%, retention time = 10.96 min.</div></div><div id="sec5_2_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>N</i>-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-3-isopropyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20c</b>)</h4><div class="NLM_p last">Yellow solid (yield 41%); mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.55 (s, 1H), 8.83 (s, 1H), 8.60 (s, 1H), 7.91 (s, 1H), 7.69 (s, 1H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.19 (d, <i>J</i> = 5.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.55–6.48 (m, 2H), 6.28 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 6.00 (s, 1H), 5.78 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.6 Hz, 1H), 5.17–5.10 (m, 1H), 3.76 (s, 3H), 3.72–3.68 (m, 2H), 3.26–3.20 (m, 1H), 2.72 (s, 6H), 2.63–2.59 (m, 2H), 2.07 (d, <i>J</i> = 10.8 Hz, 2H), 1.70–1.67 (m, 2H), 1.44 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.29, 160.19, 157.83, 139.83, 135.83, 135.95, 131.81, 129.22, 127.00, 124.26, 120.04, 119.06, 106.58, 99.91, 62.21, 55.67, 47.77, 45.00, 25.55, 19.25. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>32</sub>H<sub>39</sub>N<sub>8</sub>O<sub>4</sub> 599.3094, found 599.3079. HPLC purity: 98.38%, retention time = 11.12 min.</div></div><div id="sec5_2_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> <i>N</i>-(3-(3-Benzyl-7-((4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20d</b>)</h4><div class="NLM_p last">Yellow solid (yield 39%); mp 285.4–286.6 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 8.87 (s, 1H), 8.69 (s, 1H), 7.91 (s, 1H), 7.69 (s, 1H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.38 (d, <i>J</i> = 7.2 Hz, 2H), 7.33 (t, <i>J</i> = 7.2 Hz, 2H), 7.26 (t, <i>J</i> = 7.2 Hz, 1H), 7.19 (d, <i>J</i> = 8.0 Hz, 1H), 7.11 (d, <i>J</i> = 6.8 Hz, 1H), 6.54–6.47 (m, 2H), 6.27 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.6 Hz, 1H), 6.01–5.99 (m, 1H), 5.77 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.6 Hz, 1H), 5.10 (s, 2H), 3.76 (s, 3H), 3.72–3.69 (m, 2H), 3.27–3.21 (m, 1H), 2.73 (s, 6H), 2.62–2.57 (m, 2H), 2.08 (d, <i>J</i> = 11.2 Hz, 2H), 1.71–1.68 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.31, 159.94, 139.88, 136.98, 135.84, 131.82, 129.27, 128.30, 127.63, 127.14, 127.01, 62.24, 59.74, 55.68, 47.72, 43.83, 25.47, 20.74. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>36</sub>H<sub>39</sub>N<sub>8</sub>O<sub>4</sub> 647.3094, found 647.3088. HPLC purity: 95.30%, retention time = 12.72 min.</div></div><div id="sec5_2_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> <i>N</i>-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3-phenethyl-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20e</b>)</h4><div class="NLM_p last">Yellow solid (yield 40%); mp 196.5–197.7 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.58 (s, 1H), 8.85 (s, 1H), 8.67 (s, 1H), 7.91 (s, 1H), 7.72 (s, 1H), 7.49 (t, <i>J</i> = 8.0 Hz, 1H), 7.32 (t, <i>J</i> = 7.6 Hz, 2H), 7.26–7.23 (m, 3H), 7.19 (d, <i>J</i> = 12.8 Hz, 1H), 7.07 (d, <i>J</i> = 6.8 Hz, 1H), 6.56–6.49 (m, 2H), 6.28 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 6.01–5.99 (m, 1H), 5.78 (dd, <i>J</i> = 10.4 Hz, <i>J</i> = 1.6 Hz, 1H), 4.10–4.08 (m, 2H), 3.77 (s, 3H), 3.72–3.69 (m, 2H), 3.24–3.19 (m, 1H), 2.90 (t, <i>J</i> = 7.6 Hz, 2H), 2.71 (s, 6H), 2.62–2.57 (m, 2H), 2.07 (d, <i>J</i> = 11.2 Hz, 2H), 1.70–1.68 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.33, 159.68, 139.90, 138.51, 135.82, 131.83, 129.26, 128.59, 128.50, 127.02, 126.39, 62.23, 55.70, 47.74, 41.92, 33.28, 25.52. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>37</sub>H<sub>41</sub>N<sub>8</sub>O<sub>4</sub> 661.3251, found 661.3251. HPLC purity: 99.09%, retention time = 13.71 min.</div></div><div id="sec5_2_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> <i>N</i>-(3-(7-((4-(4-(Dimethylamino)piperidin-1-yl)-2-methoxyphenyl)amino)-2,4-dioxo-3-(3-phenylpropyl)-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20f</b>)</h4><div class="NLM_p last">Yellow solid (yield 38%); mp 252.1–253.8 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.72 (s, 1H), 8.81 (s, 1H), 8.60 (s, 1H), 7.92 (s, 1H), 7.78 (s, 1H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.28–7.19 (m, 5H), 7.14 (t, <i>J</i> = 7.2 Hz, 1H), 7.07 (d, <i>J</i> = 7.2 Hz, 1H), 6.61–6.52 (m, 2H), 6.29 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 6.02 (s, 1H), 5.78 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.6 Hz, 1H), 3.94 (t, <i>J</i> = 7.2 Hz, 2H), 3.76 (s, 3H), 3.22–3.17 (m, 1H), 2.69 (s, 6H), 2.68–2.63 (m, 4H), 2.08 (d, <i>J</i> = 10.4 Hz, 2H), 1.94 (t, <i>J</i> = 6.8 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.33, 159.89, 157.82, 141.32, 139.88, 135.89, 131.84, 129.23, 128.21, 128.12, 126.99, 125.68, 62.20, 47.76, 40.52, 32.51, 28.57, 25.57. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>38</sub>H<sub>43</sub>N<sub>8</sub>O<sub>4</sub> 675.3407, found 675.3403. HPLC purity: 95.85%, retention time = 14.42 min.</div></div><div id="sec5_2_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>N</i>-(3-(3-Isopropyl-7-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20g</b>)</h4><div class="NLM_p last">Yellow solid (yield 39%); mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 8.83 (s, 1H), 8.63 (s, 1H), 7.85 (d, <i>J</i> = 7.2 Hz, 1H), 7.73 (s, 1H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 7.20 (d, <i>J</i> = 8.4 Hz, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.56–6.51 (m, 2H), 6.27 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 6.03–6.01 (m, 1H), 5.77 (dd, <i>J</i> = 10.4 Hz, <i>J</i> = 1.2 Hz, 1H), 5.17–5.10 (m, 1H), 3.76 (s, 3H), 3.29 (t, <i>J</i> = 4.0 Hz, 4H), 3.20 (t, <i>J</i> = 4.0 Hz, 4H), 2.75 (s, 3H), 1.44 (d, <i>J</i> = 6.4 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.33, 160.20, 157.83, 139.79, 135.94, 131.79, 129.21, 127.05, 120.09, 100.00, 55.74, 52.25, 46.05, 45.02, 42.29, 19.24. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>35</sub>N<sub>8</sub>O<sub>4</sub> 571.2781, found 571.2775. HPLC purity: 98.71%, retention time = 11.25 min.</div></div><div id="sec5_2_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>N</i>-(3-(3-Isopropyl-7-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20h</b>)</h4><div class="NLM_p last">Yellow solid (yield 47%); mp 221.3–222.5 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.51 (s, 1H), 10.18 (s, 1H), 8.88 (s, 1H), 7.89 (s, 1H), 7.72 (s, 1H), 7.50 (t, <i>J</i> = 8.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 6.91 (s, 1H), 6.49 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 10.0 Hz, 1H), 6.43–6.41 (m, 1H), 6.27 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.6 Hz, 1H), 5.77 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.6 Hz, 1H), 5.18–5.11 (m, 1H), 3.56 (s, 3H), 3.04–3.01 (m, 8H), 2.63 (s, 3H), 1.44 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.29, 160.17, 151.55, 150.38, 139.87, 136.09, 134.47, 131.73, 129.33, 127.13, 124.33, 120.10, 119.23, 55.29, 53.27, 47.95, 45.06, 43.21, 19.23. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>35</sub>N<sub>8</sub>O<sub>4</sub> 571.2781, found 571.2773. HPLC purity: 97.35%, retention time = 10.11 min.</div></div><div id="sec5_2_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>N</i>-(3-(3-Isopropyl-7-((3-methyl-4-(4-methylpiperazin-1-yl)phenyl)amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20i</b>)</h4><div class="NLM_p last">Yellow solid (yield 49%); mp 295.5–296.9 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.54 (s, 1H), 10.22 (s, 1H), 8.88 (s, 1H), 7.90 (d, <i>J</i> = 7.2 Hz, 1H), 7.74 (s, 1H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 7.18 (s, 1H), 7.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.08 (d, <i>J</i> = 6.4 Hz, 1H), 6.69 (d, <i>J</i> = 7.6 Hz, 1H), 6.50 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 10.4 Hz, 1H), 6.26 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 5.76 (dd, <i>J</i> = 10.4 Hz, <i>J</i> = 1.6 Hz, 1H), 5.18–5.11 (m, 1H), 3.12 (t, <i>J</i> = 4.0 Hz, 4H), 2.92 (t, <i>J</i> = 4.0 Hz, 4H), 2.70 (s, 3H), 1.97 (s, 3H), 1.44 (d, <i>J</i> = 7.2 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.29, 160.18, 159.05, 157.91, 150.40, 139.92, 136.16, 134.60, 132.03, 131.74, 129.37, 127.10, 124.26, 121.38, 119.95, 119.35, 118.62, 117.58, 53.35, 48.94, 45.04, 42.84, 19.23, 17.44. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>35</sub>N<sub>8</sub>O<sub>3</sub> 555.2832, found 555.2831. HPLC purity: 99.05%, retention time = 10.93 min.</div></div><div id="sec5_2_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>N</i>-(3-(7-((4-((2-(Dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-3-isopropyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20j</b>)</h4><div class="NLM_p last">Yellow solid (yield 37%); mp 150.7–152.4 °C. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.94 (s, 1H), 8.45 (s, 1H), 7.95 (s, 1H), 7.83 (s, 1H), 7.68 (d, <i>J</i> = 8.0 Hz, 1H), 7.46 (t, <i>J</i> = 8.0 Hz, 1H), 7.35 (d, <i>J</i> = 8.8 Hz, 1H), 7.04 (d, <i>J</i> = 7.6 Hz, 1H), 6.38 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.6 Hz, 1H), 6.27–6.17 (m, 2H), 5.83 (dd, <i>J</i> = 9.6 Hz, <i>J</i> = 1.6 Hz, 1H), 5.69 (d, <i>J</i> = 10.4 Hz, 1H), 5.36–5.29 (m, 1H), 3.81 (s, 3H), 3.39 (t, <i>J</i> = 7.6 Hz, 2H), 2.88 (s, 3H), 2.45 (t, <i>J</i> = 7.6 Hz, 2H), 2.32 (s, 6H), 1.55 (d, <i>J</i> = 6.8 Hz, 6H). HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>30</sub>H<sub>37</sub>N<sub>8</sub>O<sub>4</sub> 573.2938, found 573.2932. HPLC purity: 95.07%, retention time = 10.56 min.</div></div><div id="sec5_2_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-(3-(7-((4-(2-(Dimethylamino)ethoxy)-2-methoxyphenyl)amino)-3-isopropyl-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20k</b>)</h4><div class="NLM_p last">Yellow solid (yield 41%); mp 195.4–196.7 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.39 (s, 1H), 8.84 (s, 1H), 8.64 (s, 1H), 7.80 (d, <i>J</i> = 4.4 Hz, 1H), 7.71 (s, 1H), 7.48 (t, <i>J</i> = 8.0 Hz, 1H), 7.23 (d, <i>J</i> = 5.6 Hz, 1H), 7.10 (d, <i>J</i> = 7.6 Hz, 1H), 6.52–6.42 (m, 2H), 6.27 (dd, <i>J</i> = 17.2 Hz, <i>J</i> = 1.6 Hz, 1H), 6.01–5.99 (m, 1H), 5.77 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.2 Hz, 1H), 5.15–5.11 (m, 1H), 3.95 (t, <i>J</i> = 5.2 Hz, 2H), 3.75 (s, 3H), 2.60 (t, <i>J</i> = 5.2 Hz, 2H), 2.22 (s, 6H), 1.44 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.19, 160.20, 159.16, 157.83, 155.23, 150.33, 139.68, 136.00, 131.65, 129.27, 127.16, 124.32, 121.37, 120.08, 119.10, 103.84, 100.07, 98.76, 65.73, 57.64, 55.73, 45.47, 44.99, 19.23. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>29</sub>H<sub>34</sub>N<sub>7</sub>O<sub>5</sub> 560.2621, found 560.2625. HPLC purity: 98.57%, retention time = 8.78 min.</div></div><div id="sec5_2_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> <i>N</i>-(3-(3-Isopropyl-7-((2-methoxy-4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl) amino)-2,4-dioxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidin-1(2<i>H</i>)-yl)phenyl)acrylamide (<b>20l</b>)</h4><div class="NLM_p last">Yellow solid (yield 43%); mp >300 °C. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.57 (s, 1H), 8.82 (s, 1H), 8.57 (s, 1H), 7.91 (s, 1H), 7.70 (s, 1H), 7.47 (t, <i>J</i> = 8.0 Hz, 1H), 7.18 (d, <i>J</i> = 6.8 Hz, 1H), 7.09 (d, <i>J</i> = 7.6 Hz, 1H), 6.56–6.49 (m, 2H), 6.27 (dd, <i>J</i> = 16.8 Hz, <i>J</i> = 1.6 Hz, 1H), 5.99–5.97 (m, 1H), 5.77 (dd, <i>J</i> = 10.0 Hz, <i>J</i> = 1.6 Hz, 1H), 5.17–5.10 (m, 1H), 3.76 (s, 3H), 3.64–3.61 (m, 2H), 2.96–2.75 (m, 6H), 2.60–2.56 (m, 6H), 1.87–1.85 (m, 1H), 1.54–1.50 (m, 2H), 1.44 (d, <i>J</i> = 6.8 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.31, 160.19, 159.07, 157.81, 150.34, 139.83, 135.92, 131.79, 129.22, 126.99, 119.99, 99.79, 60.77, 55.61, 52.86, 48.21, 46.52, 45.02, 43.23, 27.01, 19.24. HRMS (ESI) (<i>m</i>/<i>z</i>): (M + H)<sup>+</sup> calcd for C<sub>35</sub>H<sub>44</sub>N<sub>9</sub>O<sub>4</sub> 654.3516, found 654.3519. HPLC purity: 99.38%, retention time = 11.76 min.</div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> In Vitro Enzymatic Inhibition and Cell Antiproliferation Activity Assay</h3><div class="NLM_p last">The enzymatic inhibition and cell antiproliferation activity assays were evaluated by using the well-established ELISA-based assay and sulforhodamine B (SRB) colorimetric assay, respectively. The detailed experiments were performed according to the published literature,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> and the detailed characterizations are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Western Blot Analysis</h3><div class="NLM_p last">H1975 and A431 cells were collected and suspended in lysis buffer (Tris-HCl, pH 6.8, 100 mmol/L; DTT 200 mmol/L, 0.2% bromophenol blue, 4% SDS, 20% glycerol). Equivalent amounts of proteins were loaded and separated by SDS-PAGE (8%), then transferred to nitrocellulose membranes. Western blot analysis was subsequently performed with standard procedures. The antibodies were used for immune detection of proteins, including p-EGFR (Y1068; no. 3777S), EGFR (no. 4267S), p-AKT (Ser473), AKT, and GAPDH (Cell Signaling Technologies, Cambridge, MA).</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> Human and Mouse Liver Microsomal Stability Assays</h3><div class="NLM_p last">The incubation is performed as follows: microsomes in 0.1 M Tris/HCl buffer of pH 7.4 (0.33 mg/mL microsomal protein), cofactor MgCl<sub>2</sub> (5 mM), tested compound (final concentration of 0.1 μM, cosolvent (0.01% DMSO) and 0.005% bovine serum albumin) and NADPH (1 mM) at 37 °C for 60 min. The reaction can be started by the addition of liver microsomes or the tested compound or NADPH. Aliquots were sampled at 0, 7, 17, 30, and 60 min incubation, and enzymatic reaction was stopped by protein precipitation in methanol. After centrifugation, samples are then analyzed by LC-MS/MS (Waters UPLC I-Class system; Xevo TQ-S mass spectrometer).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Measurements of Aqueous Solubility, CYP Inhibition Assays, and Measurement of Permeability</h3><div class="NLM_p last">Determination of the aqueous solubility was performed according to the published literature.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The CYP inhibition assays and measurement of permeability of compound <b>20g</b> were conducted by WuXi AppTec, and the detailed characterizations are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> In Vivo Pharmacokinetics Study in Mice</h3><div class="NLM_p last">The in vivo pharmacokinetic study in mice was conducted by Shanghai Medicilon, Inc. Briefly, the dosing solution (1 mg/mL) was prepared by dissolving the appropriate amount of the compound in 0.5% CMC–Na aqueous solution for oral administration, and the 0.2 mg/mL dosing solution was prepared by dissolving the appropriate amount of the compound in mixed solvent (0.15 mL DMSO + 1.200 mL PEG400 + 1.650 mL saline) for intravenous administration. Male ICR mice were separately administered to some groups (three mice/group) for oral (10 mg/kg) or intravenous (1 mg/kg) administration. At time points 0.083, 0.25, 0.5, 1, 2, 4, 8, and 24 h after dosing, the blood sample was collected from each animal and stored in 0–4 °C, then separated by centrifugation (8000 r/min for 6 min). All samples were analyzed using LC–MS/MS (SIMADZU LC system; Applied Biosystems mass spectrometer), and the acquired data were analyzed by using the WinNonlin (v5.2).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> In Vivo Antitumor Efficiency Study</h3><div class="NLM_p last">BALB/c mice (4–6 weeks-old) were purchased from Shanghai Lab. Animal Research Center (Shanghai, China). Briefly, H1975 cell lines and A431 cell lines were cultured in RPMI-1640 (GE Healthcare) supplemented with 10% (v/v) fetal bovine serum (Gibico). Then a total volume of 0.1 mL/mouse (approximately 2 × 10<sup>6</sup> cells) were implanted subcutaneously into the right flank of the animals. When the size of the tumor reached about 200–400 mm<sup>3</sup>, the mice were randomly divided into vehicle group and treated group (six mice/group). For antitumor efficacy studies, mice were dosed once daily by oral administration with vehicle or inhibitor with the indicated dose for 14 consecutive days. The average tumor volume was measured every 2 or 3 days using vernier calipers, followed by calculating with the formula <i>V</i> = (<i>L</i> × <i>W</i><sup>2</sup>)/2, where <i>L</i> stands for length and <i>W</i> stands for width. All the animal experiments in this article, including animal handling, care, and treatment, were performed in compliance with agreement of the Ethics Committee on Laboratory Animal Care and the Guidelines for the Care and Use of Laboratory Animals in Shanghai, China.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i54"><a href="/doi/suppl/10.1021/acs.jmedchem.8b00346" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55664" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55664" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Also include availability of The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b00346" class="ext-link">10.1021/acs.jmedchem.8b00346</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Docked pose of <b>20f</b> and the metabolic stability of <b>20g</b> in human and mouse liver microsomes (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Docked <b>5</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docked <b>7</b>  (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_004.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docked <b>14a</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>C (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_005.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docked <b>20f</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>F (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_006.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Docked <b>20f</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP">2RGP</a>) Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf" class="ext-link">Figure S1</a> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_007.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf">jm8b00346_si_001.pdf (481.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_002.csv">jm8b00346_si_002.csv (2.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_003.pdb">jm8b00346_si_003.pdb (190.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_004.pdb">jm8b00346_si_004.pdb (191.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_005.pdb">jm8b00346_si_005.pdb (199.82 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_006.pdb">jm8b00346_si_006.pdb (358.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_007.pdb">jm8b00346_si_007.pdb (178.69 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b00346" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58670" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58670" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yufang Xu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#81f8e7f9f4c1e4e2f4f2f5afe4e5f4afe2ef"><span class="__cf_email__" data-cfemail="146d726c615471776167603a7170613a777a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hua Xie</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#c1a9b9a8a481aba5a8afa6efa5a9b2efaeb3a6"><span class="__cf_email__" data-cfemail="dbb3a3b2be9bb1bfb2b5bcf5bfb3a8f5b4a9bc">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Honglin Li</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2270-1900" title="Orcid link">http://orcid.org/0000-0003-2270-1900</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#bed6d2d2d7fedbddcbcdca90dbdacb90ddd0"><span class="__cf_email__" data-cfemail="dbb3b7b7b29bbeb8aea8aff5bebfaef5b8b5">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yongjia Hao</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Guizhou University of Chinese
Medicine, Guiyang 550025, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jiankun Lyu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rong Qu</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yi Tong</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deheng Sun</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fang Feng</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linjiang Tong</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tingyuan Yang</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenjiang Zhao</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lili Zhu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Key Laboratory of New Drug Design, State Key Laboratory of Bioreactor
Engineering, School of Pharmacy, East China
University of Science and Technology, Shanghai 200237, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jian Ding</span> - <span class="hlFld-Affiliation affiliation">Division
of Anti-tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy
of Sciences, Shanghai 201203, China</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Y.H., J.L., and R.Q. contributed equally.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i56">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84122" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84122" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The research is supported in part by the National Key Research and Development Program (grant 2016YFA0502304), the Shanghai Committee of Science and Technology (grant 14431902100), and the Special Program for Applied Research on Super Computation of the NSFC-Guangdong Joint Fund (the second phase) under grant no. U1501501. Honglin Li is also sponsored by National Program for Special Supports of Eminent Professionals and National Program for Support of Top-Notch Young Professionals.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">nonsmall cell lung cancer</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">TKIs</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitors</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinases</p></td></tr><tr><td class="NLM_term">TGI</td><td class="NLM_def"><p class="first last">tumor growth inhibition</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">CH<sub>3</sub>CN</td><td class="NLM_def"><p class="first last">acetonitrile</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexaflu orophosphate</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">NMP</td><td class="NLM_def"><p class="first last">1-methyl-2-pyrrolidinone</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34700" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34700" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 34 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brawley, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2011</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.3322/caac.20121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.3322%2Fcaac.20121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=21685461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BC3MnkslKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=212-236&author=R.+Siegelauthor=E.+Wardauthor=O.+Brawleyauthor=A.+Jemal&title=Cancer+statistics%2C+2011&doi=10.3322%2Fcaac.20121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths</span></div><div class="casAuthors">Siegel Rebecca; Ward Elizabeth; Brawley Otis; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">212-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  A total of 1,596,670 new cancer cases and 571,950 deaths from cancer are projected to occur in the United States in 2011.  Overall cancer incidence rates were stable in men in the most recent time period after decreasing by 1.9% per year from 2001 to 2005; in women, incidence rates have been declining by 0.6% annually since 1998.  Overall cancer death rates decreased in all racial/ethnic groups in both men and women from 1998 through 2007, with the exception of American Indian/Alaska Native women, in whom rates were stable.  African American and Hispanic men showed the largest annual decreases in cancer death rates during this time period (2.6% and 2.5%, respectively).  Lung cancer death rates showed a significant decline in women after continuously increasing since the 1930s.  The reduction in the overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 898,000 deaths from cancer.  However, this progress has not benefitted all segments of the population equally; cancer death rates for individuals with the least education are more than twice those of the most educated.  The elimination of educational and racial disparities could potentially have avoided about 37% (60,370) of the premature cancer deaths among individuals aged 25 to 64 years in 2007 alone.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population with an emphasis on those groups in the lowest socioeconomic bracket.  CA Cancer J Clin 2011. © 2011 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSV6umkq5UbgGlSCSgBhwJFfW6udTcc2eZ1GuuKXZvF27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnkslKhsg%253D%253D&md5=7fbc8af4359e652a7dd1048a031ffcc3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.20121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.20121%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DBrawley%26aufirst%3DO.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202011%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2011%26volume%3D61%26spage%3D212%26epage%3D236%26doi%3D10.3322%2Fcaac.20121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signalling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0ljgC_7gAhE80Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, H.</span></span> <span> </span><span class="NLM_article-title">A comprehensive pathway map of epidermal growth factor receptor signaling</span>. <i>Mol. Syst. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2005.0010</span>, <span class="refDoi"> DOI: 10.1038/msb4100014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fmsb4100014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=16729045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BD283psl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=2005.0010&author=K.+Odaauthor=Y.+Matsuokaauthor=A.+Funahashiauthor=H.+Kitano&title=A+comprehensive+pathway+map+of+epidermal+growth+factor+receptor+signaling&doi=10.1038%2Fmsb4100014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive pathway map of epidermal growth factor receptor signaling</span></div><div class="casAuthors">Oda Kanae; Matsuoka Yukiko; Funahashi Akira; Kitano Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular systems biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2005.0010</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) signaling pathway is one of the most important pathways that regulate growth, survival, proliferation, and differentiation in mammalian cells.  Reflecting this importance, it is one of the best-investigated signaling systems, both experimentally and computationally, and several computational models have been developed for dynamic analysis.  A map of molecular interactions of the EGFR signaling system is a valuable resource for research in this area.  In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways.  The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  The map is created using CellDesigner software that enables us to graphically represent interactions using a well-defined and consistent graphical notation, and to store it in Systems Biology Markup Language (SBML).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWCPwXSabaPEmhnSqMnvzDfW6udTcc2eZ1GuuKXZvF27ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283psl2gsg%253D%253D&md5=e5e5109cab456b01027f8bc160c4cbc9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fmsb4100014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmsb4100014%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DFunahashi%26aufirst%3DA.%26aulast%3DKitano%26aufirst%3DH.%26atitle%3DA%2520comprehensive%2520pathway%2520map%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520signaling%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2005%26volume%3D1%26spage%3D2005.0010%26doi%3D10.1038%2Fmsb4100014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer%3A+comparative+pharmacokinetics+and+drug%E2%80%93drug+interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0lgIjGjqkcKonQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520comparative%2520pharmacokinetics%2520and%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuinn, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lostritto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">United states food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-03-0564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F1078-0432.CCR-03-0564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=14977817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVCqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1212-1218&author=M.+H.+Cohenauthor=G.+A.+Williamsauthor=R.+Sridharaauthor=G.+Chenauthor=W.+D.+McGuinnauthor=D.+Morseauthor=S.+Abrahamauthor=A.+Rahmanauthor=C.+Liangauthor=R.+Lostrittoauthor=A.+Bairdauthor=R.+Pazdur&title=United+states+food+and+drug+administration+drug+approval+summary%3A+gefitinib+%28ZD1839%3B+Iressa%29+tablets&doi=10.1158%2F1078-0432.CCR-03-0564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant A.; Sridhara, Rajeshwari; Chen, Gang; McGuinn, W. David, Jr.; Morse, David; Abraham, Sophia; Rahman, Atiqur; Liang, Chenyi; Lostritto, Richard; Baird, Amy; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1212-1218</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.  Information provided in this summary includes chem. manufg. and controls, clin. pharmacol., and clin. trial efficacy and safety results.  Gefitinib is an anilinoquinazoline compd. with the chem. name 4-quinazolinamine,N-(3-chloro-4-flurophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy].  It has the mol. formula C22H24ClFN4O3.  Gefitinib is often referred to as a "specific" or "selective" inhibitor of epidermal growth factor receptor.  Studies demonstrate, however, that gefitinib inhibits the activity of other intracellular transmembrane tyrosine-specific protein kinases at concns. similar to those at which it inhibits the epidermal growth factor signal.  Maximum plasma concns. resulting from clin. relevant doses are 0.5-1 μM or more, well within the IC50 values of several tyrosine kinases.  No clin. studies have been performed that demonstrate a correlation between epidermal growth factor receptor expression and response to gefitinib.  Gefitinib is 60% available after oral administration and is widely distributed throughout the body.  Gefitinib is extensively metabolized in the liver by cytochrome P 450 3A4 enzyme.  Over a 10-day period, approx. 86% of an orally administered radioactive dose is recovered in the feces, with <4% of the dose in the urine.  After daily oral administration, steady-state plasma levels are reached in 10 days and are 2-fold higher than those achieved after single doses.  Gefitinib effectiveness was demonstrated in a randomized, double-blind, Phase II, multicenter trial comparing two oral doses of gefitinib (250 vs. 500 mg/day).  A total of 216 patients were enrolled.  The 142 patients who were refractory to or intolerant of a platinum and docetaxel comprised the evaluable population for the efficacy anal.  A partial tumor response occurred in 14% (9 of 66) of patients receiving 250 mg/day gefitinib and in 8% (6 of 76) of patients receiving 500 mg/day gefitinib.  The overall objective response rate (RR) for both doses combined was 10.6% (15 of 142 patients; 95% confidence interval, 6.0-16.8%).  Responses were more frequent in females and in nonsmokers.  The median duration of response was 7.0 mo (range, 4.6-18.6+ months).  Other submitted data included the results of two large trials conducted in chemotherapy-naive, stage III and IV non-small cell lung cancer patients.  Patients were randomized to receive gefitinib (250 or 500 mg daily) or placebo, in combination with either gemcitabine plus cisplatin (n = 1093) or carboplatin plus paclitaxel (n = 1037).  Results from this study showed no benefit (RR, time to progression, or survival) from adding gefitinib to chemotherapy.  Consequently, gefinitib is only recommended for use as monotherapy.  Common adverse events assocd. with gefitinib treatment included diarrhea, rash, acne, dry skin, nausea, and vomiting.  Interstitial lung disease has been obsd. in patients receiving gefitinib.  Worldwide, the incidence of interstitial lung disease was about 1% (2% in the Japanese post-marketing experience and about 0.3% in a United States expanded access program).  Approx. one-third of the cases have been fatal.  Gefitinib was approved under accelerated approval regulations on the basis of a surrogate end point, RR.  No controlled gefitinib trials, to date, demonstrate a clin. benefit, such as improvement in disease-related symptoms or increased survival.  Accelerated approval regulations require the sponsor to conduct addnl. studies to verify that gefitinib therapy produces such benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0OwDrydcaSLVg90H21EOLACvtfcHk0lgIjGjqkcKonQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVCqt7k%253D&md5=5dd1d0276553d177875e35357b51e6d9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-03-0564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-03-0564%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%2BA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMcGuinn%26aufirst%3DW.%2BD.%26aulast%3DMorse%26aufirst%3DD.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DLostritto%26aufirst%3DR.%26aulast%3DBaird%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DUnited%2520states%2520food%2520and%2520drug%2520administration%2520drug%2520approval%2520summary%253A%2520gefitinib%2520%2528ZD1839%253B%2520Iressa%2529%2520tablets%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D1212%26epage%3D1218%26doi%3D10.1158%2F1078-0432.CCR-03-0564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: erlotinib (Tarceva®) tablets</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.10-7-461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1634%2Ftheoncologist.10-7-461" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=461-466&author=M.+H.+Cohenauthor=J.+R.+Johnsonauthor=Y.-F.+Chenauthor=R.+Sridharaauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+erlotinib+%28Tarceva%C2%AE%29+tablets&doi=10.1634%2Ftheoncologist.10-7-461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.10-7-461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.10-7-461%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DY.-F.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520erlotinib%2520%2528Tarceva%25C2%25AE%2529%2520tablets%26jtitle%3DOncologist%26date%3D2005%26volume%3D10%26spage%3D461%26epage%3D466%26doi%3D10.1634%2Ftheoncologist.10-7-461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Soler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of non–small-cell lung cancer with erlotinib or gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1056/NEJMct0807960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1056%2FNEJMct0807960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=21388312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=947-955&author=V.+D.+Cataldoauthor=D.+L.+Gibbonsauthor=R.+P%C3%A9rez-Solerauthor=A.+Quint%C3%A1s-Cardama&title=Treatment+of+non%E2%80%93small-cell+lung+cancer+with+erlotinib+or+gefitinib&doi=10.1056%2FNEJMct0807960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span></div><div class="casAuthors">Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDIxHbNbHr7Vg90H21EOLACvtfcHk0lgIjGjqkcKonQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D&md5=5030feb97e5b6b09e3e11d6946cde577</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0807960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0807960%26sid%3Dliteratum%253Aachs%26aulast%3DCataldo%26aufirst%3DV.%2BD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DP%25C3%25A9rez-Soler%26aufirst%3DR.%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520with%2520erlotinib%2520or%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D947%26epage%3D955%26doi%3D10.1056%2FNEJMct0807960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70364-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2FS1470-2045%2809%2970364-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=20022809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=121-128&author=T.+Mitsudomiauthor=S.+Moritaauthor=Y.+Yatabeauthor=S.+Negoroauthor=I.+Okamotoauthor=J.+Tsurutaniauthor=T.+Setoauthor=M.+Satouchiauthor=H.+Tadaauthor=T.+Hirashimaauthor=K.+Asamiauthor=N.+Katakamiauthor=M.+Takadaauthor=H.+Yoshiokaauthor=K.+Shibataauthor=S.+Kudohauthor=E.+Shimizuauthor=H.+Saitoauthor=S.+Toyookaauthor=K.+Nakagawaauthor=M.+Fukuoka&title=Gefitinib+versus+cisplatin+plus+docetaxel+in+patients+with+non-small-cell+lung+cancer+harbouring+mutations+of+the+epidermal+growth+factor+receptor+%28WJTOG3405%29%3A+an+open+label%2C+randomised+phase+3+trial&doi=10.1016%2FS1470-2045%2809%2970364-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span></div><div class="casAuthors">Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Tsurutani, Junji; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.  However, whether gefitinib is better than std. platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.  We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harboring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimization technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m2, i.v.) plus docetaxel (60 mg/m2, i.v.; n=89), administered every 21 days for three to six cycles.  The primary endpoint was progression-free survival.  Survival anal. was done with the modified intention-to-treat population.  This study is registered with UMIN (University Hospital Medical Information Network in Japan), no. 000000539.  Five patients were excluded (two patients were found to have thyroid and colon cancer after randomization, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).  Thus, 172 patients (86 in each group) were included in the survival analyses.  The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel group, with a median progression-free survival time of 9.2 mo (95% CI 8.0-13.9) vs. 6.3 mo (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).  Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhea were more frequent in the gefitinib group.  Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.  Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.  Funding: West Japan Oncol. Group (WJOG): a non-profit organization supported by unrestricted donations from several pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKXuDlK2x9o7Vg90H21EOLACvtfcHk0lhNVlwSBalaVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D&md5=5856ce118d00919627e3f21525abe453</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970364-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970364-X%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNegoro%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DHirashima%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DK.%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520versus%2520cisplatin%2520plus%2520docetaxel%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%2520harbouring%2520mutations%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528WJTOG3405%2529%253A%2520an%2520open%2520label%252C%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D121%26epage%3D128%26doi%3D10.1016%2FS1470-2045%2809%2970364-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergnenegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massuti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bover, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reguart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altavilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrasa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Langa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdivia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baize, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Campelo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Abreu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Vivanco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebbia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera-Delgado, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombaron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ronco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queralt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Aguirre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70393-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2FS1470-2045%2811%2970393-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=22285168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=239-246&author=R.+Rosellauthor=E.+Carcerenyauthor=R.+Gervaisauthor=A.+Vergnenegreauthor=B.+Massutiauthor=E.+Felipauthor=R.+Palmeroauthor=R.+Garcia-Gomezauthor=C.+Pallaresauthor=J.+M.+Sanchezauthor=R.+Portaauthor=M.+Coboauthor=P.+Garridoauthor=F.+Longoauthor=T.+Moranauthor=A.+Insaauthor=F.+De+Marinisauthor=R.+Correauthor=I.+Boverauthor=A.+Illianoauthor=E.+Dansinauthor=J.+de+Castroauthor=M.+Milellaauthor=N.+Reguartauthor=G.+Altavillaauthor=U.+Jimenezauthor=M.+Provencioauthor=M.+A.+Morenoauthor=J.+Terrasaauthor=J.+Mu%C3%B1oz-Langaauthor=J.+Valdiviaauthor=D.+Islaauthor=M.+Domineauthor=O.+Molinierauthor=J.+Mazieresauthor=N.+Baizeauthor=R.+Garcia-Campeloauthor=G.+Robinetauthor=D.+Rodriguez-Abreuauthor=G.+Lopez-Vivancoauthor=V.+Gebbiaauthor=L.+Ferrera-Delgadoauthor=P.+Bombaronauthor=R.+Bernabeauthor=A.+Bearzauthor=A.+Artalauthor=E.+Cortesiauthor=C.+Rolfoauthor=M.+Sanchez-Roncoauthor=A.+Drozdowskyjauthor=C.+Queraltauthor=I.+de+Aguirreauthor=J.+L.+Ramirezauthor=J.+J.+Sanchezauthor=M.+A.+Molinaauthor=M.+Taronauthor=L.+Paz-Ares&title=Erlotinib+versus+standard+chemotherapy+as+first-line+treatment+for+european+patients+with+advanced+EGFR+mutation-positive+non-small-cell+lung+cancer+%28EURTAC%29%3A+a+multicentre%2C+open-label%2C+randomised+phase+3+trial&doi=10.1016%2FS1470-2045%2811%2970393-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span></div><div class="casAuthors">Rosell, Rafael; Carcereny, Enric; Gervais, Radj; Vergnenegre, Alain; Massuti, Bartomeu; Felip, Enriqueta; Palmero, Ramon; Garcia-Gomez, Ramon; Pallares, Cinta; Sanchez, Jose Miguel; Porta, Rut; Cobo, Manuel; Garrido, Pilar; Longo, Flavia; Moran, Teresa; Insa, Amelia; De Marinis, Filippo; Corre, Romain; Bover, Isabel; Illiano, Alfonso; Dansin, Eric; de Castro, Javier; Milella, Michele; Reguart, Noemi; Altavilla, Giuseppe; Jimenez, Ulpiano; Provencio, Mariano; Moreno, Miguel Angel; Terrasa, Josefa; Munoz-Langa, Jose; Valdivia, Javier; Isla, Dolores; Domine, Manuel; Molinier, Olivier; Mazieres, Julien; Baize, Nathalie; Garcia-Campelo, Rosario; Robinet, Gilles; Rodriguez-Abreu, Delvys; Lopez-Vivanco, Guillermo; Gebbia, Vittorio; Ferrera-Delgado, Lioba; Bombaron, Pierre; Bernabe, Reyes; Bearz, Alessandra; Artal, Angel; Cortesi, Enrico; Rolfo, Christian; Sanchez-Ronco, Maria; Drozdowskyj, Ana; Queralt, Cristina; de Aguirre, Itziar; Ramirez, Jose Luis; Sanchez, Jose Javier; Molina, Miguel Angel; Taron, Miquel; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-246</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations.  We aimed to assess the safety and efficacy of erlotinib compared with std. chemotherapy for first-line treatment of European patients with advanced EGFR-mutation pos. NSCLC.  Methods: We undertook the open-label, randomized phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain.  Eligible participants were adults (>18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥6 mo before study entry was allowed).  We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 wk cycles of std. i.v. chemotherapy of cisplatin 75 mg/m2 on day 1 plus docetaxel (75 mg/m2 on day 1) or gemcitabine (1250 mg/m2 on days 1 and 8).  Carboplatin (AUC 6 with docetaxel 75 mg/m2 or AUC 5 with gemcitabine 1000 mg/m2) was allowed in patients unable to have cisplatin.  Patients were stratified by EGFR mutation type and Eastern Cooperative Oncol. Group performance status (0 vs 1 vs 2).  The primary endpoint was progression-free survival (PFS) in the intention-to-treat population.  We assessed safety in all patients who received study drug (≥1 dose).  This study is registered with ClinicalTrials.gov, no. NCT00446225.  Findings: Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled.  One patient received treatment before randomization and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive std. chemotherapy.  The preplanned interim anal. showed that the study met its primary endpoint; enrollment was halted, and full evaluation of the results was recommended.  At data cutoff (Jan 26, 2011), median PFS was 9·7 mo (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 mo (4·5-5·8) in the std. chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p<0·0001).  Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anemia (one [1%] vs three [4%]), and increased amino-transferase concns. (two [2%] vs 0).  Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy.  One patient in the erlotinib group and two in the std. chemotherapy group died from treatment-related causes.  Interpretation: Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-pos. patients with EGFR tyrosine-kinase inhibitors.  Funding: Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Tematica de Investigacion Cooperativa en Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHsqWOF3EU7Vg90H21EOLACvtfcHk0lhNVlwSBalaVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D&md5=9b7c83e16707fba2bc2f4a878effbfb3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970393-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970393-X%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DGervais%26aufirst%3DR.%26aulast%3DVergnenegre%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DGarcia-Gomez%26aufirst%3DR.%26aulast%3DPallares%26aufirst%3DC.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DGarrido%26aufirst%3DP.%26aulast%3DLongo%26aufirst%3DF.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26aulast%3DCorre%26aufirst%3DR.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DIlliano%26aufirst%3DA.%26aulast%3DDansin%26aufirst%3DE.%26aulast%3Dde%2BCastro%26aufirst%3DJ.%26aulast%3DMilella%26aufirst%3DM.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DJimenez%26aufirst%3DU.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DTerrasa%26aufirst%3DJ.%26aulast%3DMu%25C3%25B1oz-Langa%26aufirst%3DJ.%26aulast%3DValdivia%26aufirst%3DJ.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DMolinier%26aufirst%3DO.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DBaize%26aufirst%3DN.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DRodriguez-Abreu%26aufirst%3DD.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DGebbia%26aufirst%3DV.%26aulast%3DFerrera-Delgado%26aufirst%3DL.%26aulast%3DBombaron%26aufirst%3DP.%26aulast%3DBernabe%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DArtal%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DE.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DRamirez%26aufirst%3DJ.%2BL.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DErlotinib%2520versus%2520standard%2520chemotherapy%2520as%2520first-line%2520treatment%2520for%2520european%2520patients%2520with%2520advanced%2520EGFR%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520%2528EURTAC%2529%253A%2520a%2520multicentre%252C%2520open-label%252C%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D239%26epage%3D246%26doi%3D10.1016%2FS1470-2045%2811%2970393-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lh5D6zvjFc1sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. irreversible inhibitors of the epidermal growth factor receptor:  4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A%E2%80%89+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25E2%2580%2589%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek-Klumpers, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalak, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0lhnSLorZsrBXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zejnullahu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">11924</span>– <span class="NLM_lpage">11932</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=18089823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; Gonzales, Andrea J.; Shimamura, Takeshi; Zhao, Feng; Vincent, Patrick W.; Naumov, George N.; Bradner, James E.; Althaus, Irene W.; Gandhi, Leena; Shapiro, Geoffrey I.; Nelson, James M.; Heymach, John V.; Meyerson, Matthew; Wong, Kwok-Kin; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11924-11932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers.  In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents.  However, despite their initial response, such cancers almost invariably develop resistance.  In 50% of such cancers, a secondary EGFR mutation, T790M, has been identified that renders gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.  Thus, there is a clin. need to develop novel EGFR inhibitors that can effectively inactivate T790M-contg. EGFR proteins.  In this study, we evaluate the effectiveness of a novel compd., PF00299804, an irreversible pan-ERBB inhibitor.  The results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo.  Addnl., PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.  These preclin. evaluations support further clin. development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members. [Cancer Res 2007;67(24):11924-32].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02Cx_x26RirVg90H21EOLACvtfcHk0lhnSLorZsrBXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL&md5=c210cf2fb3d1479df5915d317259696f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4702</span>– <span class="NLM_lpage">4711</span>, <span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0lg_OVs3USzxOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+Dungoauthor=G.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0lg_OVs3USzxOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%26aulast%3DKeating%26aufirst%3DG.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-lung 1): a phase 2b/3 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.-M.+Chenauthor=K.+Parkauthor=S.-W.+Kimauthor=C.+Zhouauthor=W.-C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.-H.+Tanauthor=T.-Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.-H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lg_OVs3USzxOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-M.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgBQV67IEwobQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgBQV67IEwobQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tjin
Tham Sjin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medikonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1468</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+Tjin%0ATham+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+vitro+and+in+vivo+characterization+of+irreversible+mutant-selective+EGFR+inhibitors+that+are+wild-type+sparing&doi=10.1158%2F1535-7163.MCT-13-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span></div><div class="casAuthors">Tjin Tham Sjin Robert; Lee Kwangho; Walter Annette O; Dubrovskiy Aleksandr; Sheets Michael; Martin Thia St; Labenski Matthew T; Zhu Zhendong; Tester Richland; Karp Russell; Medikonda Aravind; Chaturvedi Prasoon; Ren Yixuan; Haringsma Henry; Etter Jeff; Raponi Mitch; Simmons Andrew D; Harding Thomas C; Niu Deqiang; Nacht Mariana; Westlin William F; Petter Russell C; Allen Andrew; Singh Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)).  These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT).  Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT).  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT).  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT).  Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors.  Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdUiOZStIjAqx48Rj5GnGofW6udTcc2eZzyZSqtY6lmbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D&md5=b42556f3737b33c07511a77ab63ed1d1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520irreversible%2520mutant-selective%2520EGFR%2520inhibitors%2520that%2520are%2520wild-type%2520sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479%26doi%3D10.1158%2F1535-7163.MCT-13-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7048</span>, <span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+%C3%89.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lgAGwckYAavrQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2B%25C3%2589.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lg09K8I8sCu0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span> <i>FDA Approves New Pill to Treat Certain Patients
with Non-Small Cell
Lung Cancer</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, November 13, <span class="NLM_year">2015</span>; <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+New+Pill+to+Treat+Certain+Patients%0Awith+Non-Small+Cell%0ALung+Cancer%3B+U.S.+Food+and+Drug+Administration%2C+November+13%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm472525.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520New%2520Pill%2520to%2520Treat%2520Certain%2520Patients%250Awith%2520Non-Small%2520Cell%250ALung%2520Cancer%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of C4-alkyl-1,4-dihydro-2hpyrimido[4,5-<i>d</i>][1,3]oxazin-2-ones as potent and mutant-selective epidermal growth factor receptor (EGFR) L858R/T790M inhibitors</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3830</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-04184-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fs41598-017-04184-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=28630494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BC1cnpvVKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3830&author=Y.+Haoauthor=J.+Lyuauthor=R.+Quauthor=D.+Sunauthor=Z.+Zhaoauthor=Z.+Chenauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xuauthor=H.+Li&title=Structure-guided+design+of+C4-alkyl-1%2C4-dihydro-2hpyrimido%5B4%2C5-d%5D%5B1%2C3%5Doxazin-2-ones+as+potent+and+mutant-selective+epidermal+growth+factor+receptor+%28EGFR%29+L858R%2FT790M+inhibitors&doi=10.1038%2Fs41598-017-04184-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors</span></div><div class="casAuthors">Hao Yongjia; Lyu Jiankun; Sun Deheng; Zhao Zhenjiang; Chen Zhuo; Xu Yufang; Li Honglin; Qu Rong; Ding Jian; Xie Hua; Qu Rong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3830</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer.  Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a series of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors.  Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFR(L858R/T790M) (H1975 cell lines) over EGFR(WT) (A431 cell lines).  The representative compound 20a also showed promising antitumor efficiency in the in vivo antitumor efficacy study of H1975 xenograft mouse model driven by EGFR(L858R/T790M).  These results provide a new scaffold for the treatment of dual-mutant-driven non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ773w9Z4f3GRFwe7cAcrfPfW6udTcc2eafLqAkaGmdC7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnpvVKntw%253D%253D&md5=63f89dc099aae0289c1c39d4549d795d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-04184-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-04184-9%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DStructure-guided%2520design%2520of%2520C4-alkyl-1%252C4-dihydro-2hpyrimido%255B4%252C5-d%255D%255B1%252C3%255Doxazin-2-ones%2520as%2520potent%2520and%2520mutant-selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520L858R%252FT790M%2520inhibitors%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D3830%26doi%3D10.1038%2Fs41598-017-04184-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagara, K.</span></span> <span> </span><span class="NLM_article-title">The process development of a novel aldose reductase inhibitor, FK366. part 1. Improvement of discovery process and new syntheses of 1-substituted quinazolinediones</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1021/op0340661</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0340661" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1artbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=700-706&author=S.+Gotoauthor=H.+Tsuboiauthor=M.+Kanodaauthor=K.+Mukaiauthor=K.+Kagara&title=The+process+development+of+a+novel+aldose+reductase+inhibitor%2C+FK366.+part+1.+Improvement+of+discovery+process+and+new+syntheses+of+1-substituted+quinazolinediones&doi=10.1021%2Fop0340661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Process Development of a Novel Aldose Reductase Inhibitor, FK366. Part 1. Improvement of Discovery Process and New Syntheses of 1-Substituted Quinazolinediones</span></div><div class="casAuthors">Goto, Shunsuke; Tsuboi, Hiroyuki; Kanoda, Masami; Mukai, Koji; Kagara, Kooji</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">700-706</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel aldose reductase inhibitor FK366 I is prepd. on multikilogram scale by an improved, practical and cost-effective process.  Addn. of base to a soln. of 2-amino-4-chlorobenzoic acid followed by addn. of sodium cyanate at pH 6-7 and a second treatment with aq. sodium hydroxide yields the quinazoline II; the pH is carefully controlled in the cyanate addn. step by addn. of hydrochloric acid to the reaction mixt., preventing the decompn. of cyanate while allowing the cyclocondensation reaction to occur at a reasonable rate.  Silylation of II with bis(trimethylsilyl)amide in the presence of sulfuric acid (with careful mixing of bis(trimethylsilyl)amide and sulfuric acid to avoid violent reaction) yields an intermediate bis(trimethylsilyloxy)quinazoline which undergoes regioselective alkylation in Et acetate to provide the intermediate III in good yield as a single regioisomer.  Alkylation of the remaining free nitrogen of the quinazoline with 4-bromo-2-fluorobenzyl bromide followed by basic hydrolysis of the ethoxycarbonyl moiety yields I on 35 kg scale.  The dibenzylated quinazoline IV, resulting from incomplete reaction of II in the regioselective alkylation reaction with Et bromoacetate followed by subsequent dibenzylation, acts as a initiator for the formation of an undesired polymorph of I which is difficult to filter and which forms thick slurries.  Seeding solns. of I contg. ≥1% of IV with either polymorph of I results in crystn. of the undesired polymorph of I from soln.  Solns. with 0.5% IV yield different polymorphs depending on the identity of the seed crystal; seeding the soln. with a crystal of the undesired polymorph of I provides crystals of the undesired polymorph of I, while seeding the soln. with a crystal of the desired polymorph of I results in crystn. of the desired polymorph of I.  Monitoring of the initial silylation and regioselective alkylation step by HPLC is used to minimize the amt. of IV present in the final product and thus to provide the desired polymorph of I upon recrystn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIV9IE_Zlkh7Vg90H21EOLACvtfcHk0lhmyflI7SE0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1artbo%253D&md5=9ef93282259eecc62e8644c0953fd652</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fop0340661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0340661%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DTsuboi%26aufirst%3DH.%26aulast%3DKanoda%26aufirst%3DM.%26aulast%3DMukai%26aufirst%3DK.%26aulast%3DKagara%26aufirst%3DK.%26atitle%3DThe%2520process%2520development%2520of%2520a%2520novel%2520aldose%2520reductase%2520inhibitor%252C%2520FK366.%2520part%25201.%2520Improvement%2520of%2520discovery%2520process%2520and%2520new%2520syntheses%2520of%25201-substituted%2520quinazolinediones%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2003%26volume%3D7%26spage%3D700%26epage%3D706%26doi%3D10.1021%2Fop0340661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and structural optimization of N5-substituted 6, 7-dioxo-6, 7-dihydropteridines as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7111</span>– <span class="NLM_lpage">7124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00403</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00403" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7111-7124&author=Y.+Haoauthor=X.+Wangauthor=T.+Zhangauthor=D.+Sunauthor=Y.+Tongauthor=Y.+Xuauthor=H.+Chenauthor=L.+Tongauthor=L.+Zhuauthor=Z.+Zhaoauthor=Z.+Chenauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xuauthor=H.+Li&title=Discovery+and+structural+optimization+of+N5-substituted+6%2C+7-dioxo-6%2C+7-dihydropteridines+as+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+L858R%2FT790M+resistance+mutation&doi=10.1021%2Facs.jmedchem.6b00403"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520structural%2520optimization%2520of%2520N5-substituted%25206%252C%25207-dioxo-6%252C%25207-dihydropteridines%2520as%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520L858R%252FT790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7111%26epage%3D7124%26doi%3D10.1021%2Facs.jmedchem.6b00403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span> <i>Maestro</i>, <span class="NLM_edition">version 9.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Maestro%2C+version+9.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lhmyflI7SE0Sg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2Fj.phrs.2015.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=26529477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=26-48&author=R.+Roskoski&title=Classification+of+small+molecule+protein+kinase+inhibitors+based+upon+the+structures+of+their+drug-enzyme+complexes&doi=10.1016%2Fj.phrs.2015.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-48</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because dysregulation and mutations of protein kinases play causal roles in human disease, this family of enzymes has become one of the most important drug targets over the past two decades.  The X-ray crystal structures of 21 of the 27 FDA-approved small mol. inhibitors bound to their target protein kinases are depicted in this paper.  The structure of the enzyme-bound antagonist complex is used in the classification of these inhibitors.  Type I inhibitors bind to the active protein kinase conformation (DFG-Asp in, αC-helix in).  Type I1/2 inhibitors bind to a DFG-Asp in inactive conformation while Type II inhibitors bind to a DFG-Asp out inactive conformation.  Type I, I1/2, and type II inhibitors occupy part of the adenine binding pocket and form hydrogen bonds with the hinge region connecting the small and large lobes of the enzyme.  Type III inhibitors bind next to the ATP-binding pocket and type IV inhibitors do not bind to the ATP or peptide substrate binding sites.  Type III and IV inhibitors are allosteric in nature.  Type V inhibitors bind to two different regions of the protein kinase domain and are therefore bivalent inhibitors.  The type I-V inhibitors are reversible.  In contrast, type VI inhibitors bind covalently to their target enzyme.  Type I, I1/2, and II inhibitors are divided into A and B subtypes.  The type A inhibitors bind in the front cleft, the back cleft, and near the gatekeeper residue, all of which occur within the region sepg. the small and large lobes of the protein kinase.  The type B inhibitors bind in the front cleft and gate area but do not extend into the back cleft.  An anal. of the limited available data indicates that type A inhibitors have a long residence time (minutes to hours) while the type B inhibitors have a short residence time (seconds to minutes).  The catalytic spine includes residues from the small and large lobes and interacts with the adenine ring of ATP.  Nearly all of the approved protein kinase inhibitors occupy the adenine-binding pocket; thus it is not surprising that these inhibitors interact with nearby catalytic spine (CS) residues.  Moreover, a significant no. of approved drugs also interact with regulatory spine (RS) residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0COwqC0CabVg90H21EOLACvtfcHk0lgXySqB5vt8ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN&md5=e6b45c8644e322f30f898e763780c64b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DClassification%2520of%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%2520based%2520upon%2520the%2520structures%2520of%2520their%2520drug-enzyme%2520complexes%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D103%26spage%3D26%26epage%3D48%26doi%3D10.1016%2Fj.phrs.2015.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2711</span>– <span class="NLM_lpage">2723</span>, <span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of pteridin-7(8<i>H</i>)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7821</span>– <span class="NLM_lpage">7837</span>, <span class="refDoi"> DOI: 10.1021/jm401045n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401045n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7821-7837&author=W.+Zhouauthor=X.+Liuauthor=Z.+Tuauthor=L.+Zhangauthor=X.+Kuauthor=F.+Baiauthor=Z.+Zhaoauthor=Y.+Xuauthor=K.+Dingauthor=H.+Li&title=Discovery+of+pteridin-7%288H%29-one-based+irreversible+inhibitors+targeting+the+epidermal+growth+factor+receptor+%28EGFR%29+kinase+T790M%2FL858R+mutant&doi=10.1021%2Fjm401045n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401045n%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520pteridin-7%25288H%2529-one-based%2520irreversible%2520inhibitors%2520targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520T790M%252FL858R%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7821%26epage%3D7837%26doi%3D10.1021%2Fjm401045n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8803</span>– <span class="NLM_lpage">8813</span>, <span class="refDoi"> DOI: 10.1021/jm4012388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8803-8813&author=S.+Xuauthor=T.+Xuauthor=L.+Zhangauthor=Z.+Zhangauthor=J.+Luoauthor=Y.+Liuauthor=X.+Luauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+2-oxo-3%2C4-dihydropyrimido%5B4%2C5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+epidermal+growth+factor+receptor+inhibitors+with+improved+pharmacokinetic+properties&doi=10.1021%2Fjm4012388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25202-oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8803%26epage%3D8813%26doi%3D10.1021%2Fjm4012388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2385</span>, <span class="refDoi"> DOI: 10.1021/ci200060s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200060s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKmtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2372-2385&author=X.+Liuauthor=H.+Jiangauthor=H.+Li&title=SHAFTS%3A+a+hybrid+approach+for+3D+molecular+similarity+calculation.+1.+Method+and+assessment+of+virtual+screening&doi=10.1021%2Fci200060s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 1. Method and Assessment of Virtual Screening</span></div><div class="casAuthors">Liu, Xiaofeng; Jiang, Hualiang; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2372-2385</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed a novel approach called SHAFTS (SHApe-FeaTure Similarity) for 3D mol. similarity calcn. and ligand-based virtual screening.  SHAFTS adopts a hybrid similarity metric combined with mol. shape and colored (labeled) chem. groups annotated by pharmacophore features for 3D similarity calcn. and ranking, which is designed to integrate the strength of pharmacophore matching and volumetric overlay approaches.  A feature triplet hashing method is used for fast mol. alignment poses enumeration, and the optimal superposition between the target and the query mols. can be prioritized by calcg. corresponding "hybrid similarities".  SHAFTS is suitable for large-scale virtual screening with single or multiple bioactive compds. as the query "templates" regardless of whether corresponding exptl. detd. conformations are available.  Two public test sets (DUD and Jain's sets) including active and decoy mols. from a panel of useful drug targets were adopted to evaluate the virtual screening performance.  SHAFTS outperformed several other widely used virtual screening methods in terms of enrichment of known active compds. as well as novel chemotypes, thereby indicating its robustness in hit compds. identification and potential of scaffold hopping in virtual screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2vWrL-rCNmrVg90H21EOLACvtfcHk0lhBAYxrTlC9lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKmtbbO&md5=3733bf9faa6c5ac8945e6ec4a5d365b9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fci200060s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200060s%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DSHAFTS%253A%2520a%2520hybrid%2520approach%2520for%25203D%2520molecular%2520similarity%2520calculation.%25201.%2520Method%2520and%2520assessment%2520of%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2372%26epage%3D2385%26doi%3D10.1021%2Fci200060s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1829</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btt270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1093%2Fbioinformatics%2Fbtt270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=23712658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=1827-1829&author=J.+Gongauthor=C.+Caiauthor=X.+Liuauthor=X.+Kuauthor=H.+Jiangauthor=D.+Gaoauthor=H.+Li&title=ChemMapper%3A+a+versatile+web+server+for+exploring+pharmacology+and+chemical+structure+association+based+on+molecular+3D+similarity+method&doi=10.1093%2Fbioinformatics%2Fbtt270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method</span></div><div class="casAuthors">Gong, Jiayu; Cai, Chaoqian; Liu, Xiaofeng; Ku, Xin; Jiang, Hualiang; Gao, Daqi; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1827-1829</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Summary: ChemMapper is an online platform to predict polypharmacol. effect and mode of action for small mols. based on 3D similarity computation.  ChemMapper collects >350 000 chem. structures with bioactivities and assocd. target annotations (as well as >3 000 000 non-annotated compds. for virtual screening).  Taking the user-provided chem. structure as the query, the top most similar compds. in terms of 3D similarity are returned with assocd. pharmacol. annotations.  ChemMapper is designed to provide versatile services in a variety of chemogenomics, drug repurposing, polypharmacol., novel bioactive compds. identification and scaffold hopping studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSkcKTpsV3rVg90H21EOLACvtfcHk0lhBAYxrTlC9lw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjsrbN&md5=b13c728b5b001074ab41315be24231e1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtt270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtt270%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DChemMapper%253A%2520a%2520versatile%2520web%2520server%2520for%2520exploring%2520pharmacology%2520and%2520chemical%2520structure%2520association%2520based%2520on%2520molecular%25203D%2520similarity%2520method%26jtitle%3DBioinformatics%26date%3D2013%26volume%3D29%26spage%3D1827%26epage%3D1829%26doi%3D10.1093%2Fbioinformatics%2Fbtt270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span> <span> </span><span class="NLM_article-title">New artificial fluoro-cofactor of hydride transfer with novel fluorescence assay for redox biocatalysis</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6471</span>– <span class="NLM_lpage">6474</span>, <span class="refDoi"> DOI: 10.1039/C6CC02002J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1039%2FC6CC02002J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=6471-6474&author=L.+Zhangauthor=J.+Yuanauthor=Y.+Xuauthor=Y.+H.+P.+Zhangauthor=X.+Qian&title=New+artificial+fluoro-cofactor+of+hydride+transfer+with+novel+fluorescence+assay+for+redox+biocatalysis&doi=10.1039%2FC6CC02002J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC6CC02002J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC02002J%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BH.%2BP.%26aulast%3DQian%26aufirst%3DX.%26atitle%3DNew%2520artificial%2520fluoro-cofactor%2520of%2520hydride%2520transfer%2520with%2520novel%2520fluorescence%2520assay%2520for%2520redox%2520biocatalysis%26jtitle%3DChem.%2520Commun.%26date%3D2016%26volume%3D52%26spage%3D6471%26epage%3D6474%26doi%3D10.1039%2FC6CC02002J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Mami Sato, Hirokazu Fuchida, Naoya Shindo, Keiko Kuwata, Keisuke Tokunaga, Guo Xiao-Lin, Ryo Inamori, Keitaro Hosokawa, Kosuke Watari, Tomohiro Shibata, Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo, Mayumi Ono, <span class="NLM_string-name hlFld-ContribAuthor">Akio Ojida</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Covalent Targeting of Mutated EGFR(T790M) with Chlorofluoroacetamide-Pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (6)
                                     , 1137-1144. <a href="https://doi.org/10.1021/acsmedchemlett.9b00574" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.9b00574</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.9b00574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.9b00574%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DSelective%252BCovalent%252BTargeting%252Bof%252BMutated%252BEGFR%252528T790M%252529%252Bwith%252BChlorofluoroacetamide-Pyrimidines%26aulast%3DSato%26aufirst%3DMami%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D04122019%26date%3D08042020%26date%3D10042020%26date%3D08042020%26volume%3D11%26issue%3D6%26spage%3D1137%26epage%3D1144" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eman A.  Fayed</span>, <span class="hlFld-ContribAuthor ">Yousry A.  Ammar</span>, <span class="hlFld-ContribAuthor ">Marwa A.  Saleh</span>, <span class="hlFld-ContribAuthor ">Ashraf H.  Bayoumi</span>, <span class="hlFld-ContribAuthor ">Amany  Belal</span>, <span class="hlFld-ContribAuthor ">Ahmed B.M.  Mehany</span>, <span class="hlFld-ContribAuthor ">Ahmed  Ragab</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, antiproliferative evaluation, and molecular docking study of new quinoxaline derivatives as apoptotic inducers and EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Molecular Structure</span><span> <strong>2021,</strong> <em>1236 </em>, 130317. <a href="https://doi.org/10.1016/j.molstruc.2021.130317" title="DOI URL">https://doi.org/10.1016/j.molstruc.2021.130317</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.molstruc.2021.130317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.molstruc.2021.130317%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Molecular%2520Structure%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bantiproliferative%252Bevaluation%25252C%252Band%252Bmolecular%252Bdocking%252Bstudy%252Bof%252Bnew%252Bquinoxaline%252Bderivatives%252Bas%252Bapoptotic%252Binducers%252Band%252BEGFR%252Binhibitors%26aulast%3DFayed%26aufirst%3DEman%2BA.%26date%3D2021%26volume%3D1236%26spage%3D130317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammed M.S.  Wassel</span>, <span class="hlFld-ContribAuthor ">Yousry A.  Ammar</span>, <span class="hlFld-ContribAuthor ">Gameel A.M.  Elhag Ali</span>, <span class="hlFld-ContribAuthor ">Amany  Belal</span>, <span class="hlFld-ContribAuthor ">Ahmed B.M.  Mehany</span>, <span class="hlFld-ContribAuthor ">Ahmed  Ragab</span>. </span><span class="cited-content_cbyCitation_article-title">Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: Design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>110 </em>, 104794. <a href="https://doi.org/10.1016/j.bioorg.2021.104794" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104794</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104794%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDevelopment%252Bof%252Badamantane%252Bscaffold%252Bcontaining%252B1%25252C3%25252C4-thiadiazole%252Bderivatives%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Banti-proliferative%252Bactivity%252Band%252Bmolecular%252Bdocking%252Bstudy%252Btargeting%252BEGFR%26aulast%3DWassel%26aufirst%3DMohammed%2BM.S.%26date%3D2021%26volume%3D110%26spage%3D104794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wan‐Chen  Pan</span>, <span class="hlFld-ContribAuthor ">Yi‐Chun  Wang</span>, <span class="hlFld-ContribAuthor ">Tuan‐Jie  Li</span>, <span class="hlFld-ContribAuthor ">Jian‐Quan  Liu</span>, <span class="hlFld-ContribAuthor ">Xiang‐Shan  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">An efficient synthesis of 6‐benzyl‐2‐arylthieno[2,3‐
              d
              ]pyrimidin‐4(
              
                3
                H
              
              )‐ones catalyzed by
              HCl
              involving a
              Friedel‐Crafts
              alkylation reaction. </span><span class="cited-content_cbyCitation_journal-name">Journal of Heterocyclic Chemistry</span><span> <strong>2020,</strong> <em>57 </em>
                                    (11)
                                     , 3970-3979. <a href="https://doi.org/10.1002/jhet.4107" title="DOI URL">https://doi.org/10.1002/jhet.4107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jhet.4107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjhet.4107%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Heterocyclic%2520Chemistry%26atitle%3DAn%252Befficient%252Bsynthesis%252Bof%252B6%2525E2%252580%252590benzyl%2525E2%252580%2525902%2525E2%252580%252590arylthieno%25255B2%25252C3%2525E2%252580%252590%252Bd%252B%25255Dpyrimidin%2525E2%252580%2525904%252528%252B3%252BH%252B%252529%2525E2%252580%252590ones%252Bcatalyzed%252Bby%252BHCl%252Binvolving%252Ba%252BFriedel%2525E2%252580%252590Crafts%252Balkylation%252Breaction%26aulast%3DPan%26aufirst%3DWan%25E2%2580%2590Chen%26date%3D2020%26date%3D2020%26volume%3D57%26issue%3D11%26spage%3D3970%26epage%3D3979" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md Azhar  Iqbal</span>, <span class="hlFld-ContribAuthor ">Asif  Husain</span>, <span class="hlFld-ContribAuthor ">Ozair  Alam</span>, <span class="hlFld-ContribAuthor ">Shah A.  Khan</span>, <span class="hlFld-ContribAuthor ">Aftab  Ahmad</span>, <span class="hlFld-ContribAuthor ">Md Rafi  Haider</span>, <span class="hlFld-ContribAuthor ">Md Aftab  Alam</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of imidazopyridine‐linked thiazolidinone as potential anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2020,</strong> <em>353 </em>
                                    (10)
                                     , 2000071. <a href="https://doi.org/10.1002/ardp.202000071" title="DOI URL">https://doi.org/10.1002/ardp.202000071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.202000071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.202000071%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bimidazopyridine%2525E2%252580%252590linked%252Bthiazolidinone%252Bas%252Bpotential%252Banticancer%252Bagents%26aulast%3DIqbal%26aufirst%3DMd%2BAzhar%26date%3D2020%26date%3D2020%26volume%3D353%26issue%3D10%26spage%3D2000071" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pascale  Moreau</span>, <span class="hlFld-ContribAuthor ">Fabrice  Anizon</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6-6 Systems: Other Four Heteroatoms 2/2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-409547-2.14956-X" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.14956-X</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.14956-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.14956-X%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B6-6%252BSystems%25253A%252BOther%252BFour%252BHeteroatoms%252B2%25252F2%26aulast%3DMoreau%26aufirst%3DPascale%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M.  Monier</span>, <span class="hlFld-ContribAuthor ">Doaa  Abdel-Latif</span>, <span class="hlFld-ContribAuthor ">Ahmed  El-Mekabaty</span>, <span class="hlFld-ContribAuthor ">Khaled M.  Elattar</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 6 + 6 systems: the chemistry of pyrimido[4,5-
              d
              ]pyrimidines and pyrimido[5,4-
              d
              ]pyrimidines. </span><span class="cited-content_cbyCitation_journal-name">RSC Advances</span><span> <strong>2019,</strong> <em>9 </em>
                                    (53)
                                     , 30835-30867. <a href="https://doi.org/10.1039/C9RA05687D" title="DOI URL">https://doi.org/10.1039/C9RA05687D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9RA05687D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9RA05687D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Advances%26atitle%3DBicyclic%252B6%252B%25252B%252B6%252Bsystems%25253A%252Bthe%252Bchemistry%252Bof%252Bpyrimido%25255B4%25252C5-%252Bd%252B%25255Dpyrimidines%252Band%252Bpyrimido%25255B5%25252C4-%252Bd%252B%25255Dpyrimidines%26aulast%3DMonier%26aufirst%3DM.%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D53%26spage%3D30835%26epage%3D30867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanyan  Diao</span>, <span class="hlFld-ContribAuthor ">Xiaoyu  Fang</span>, <span class="hlFld-ContribAuthor ">Peiran  Song</span>, <span class="hlFld-ContribAuthor ">Mengzhen  Lai</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Dou  Dou</span>, <span class="hlFld-ContribAuthor ">Yingqiang  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Biological evaluation of pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione derivatives as potent Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3390-3395. <a href="https://doi.org/10.1016/j.bmc.2019.06.023" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.06.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.06.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.06.023%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BBiological%252Bevaluation%252Bof%252Bpyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-dione%252Bderivatives%252Bas%252Bpotent%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DDiao%26aufirst%3DYanyan%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3390%26epage%3D3395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaoqi  He</span>, <span class="hlFld-ContribAuthor ">Yiping  Song</span>, <span class="hlFld-ContribAuthor ">Wenhao  Wei</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Xingjian  Lu</span>, <span class="hlFld-ContribAuthor ">Honglin  Li</span>. </span><span class="cited-content_cbyCitation_article-title">eSHAFTS: Integrated and graphical drug design software based on 3D molecular similarity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Chemistry</span><span> <strong>2019,</strong> <em>40 </em>
                                    (6)
                                     , 826-838. <a href="https://doi.org/10.1002/jcc.25769" title="DOI URL">https://doi.org/10.1002/jcc.25769</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcc.25769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcc.25769%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Chemistry%26atitle%3DeSHAFTS%25253A%252BIntegrated%252Band%252Bgraphical%252Bdrug%252Bdesign%252Bsoftware%252Bbased%252Bon%252B3D%252Bmolecular%252Bsimilarity%26aulast%3DHe%26aufirst%3DGaoqi%26date%3D2019%26date%3D2019%26volume%3D40%26issue%3D6%26spage%3D826%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0012.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of representative first-, second-, and third-generation EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione Derivatives <b>14a</b>–<b>e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>3</sub>OH, rt, 24 h, 64%; (b) ethyl 2,4-dichloropyrimidine-5-carboxylate, DIPEA, CH<sub>3</sub>CN, reflux, 2 h, 86%; (c) 1 M NaOH, THF, 50 °C, 3 h, 96%; (d) arylamine, CH<sub>3</sub>CN, reflux, overnight, 42–89%; (e) methylamine hydrochloride, HATU, DIPEA, dry DMF, rt, overnight, 31–47%; (f) 1,1′-carbonyldiimidazole, K<sub>2</sub>CO<sub>3</sub>, dry THF, reflux, overnight, 35–42%; (g) trifluoroacetic acid, CH<sub>2</sub>Cl<sub>2</sub>, rt, 4 h, 81–90%; (h) acrylyl chloride, NMP/CH<sub>3</sub>CN, 0 °C to rt, overnight, 47–53%.</p></p></figure><figure data-id="sch2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Pyrimido[4,5-<i>d</i>]pyrimidine-2,4(1<i>H</i>,3<i>H</i>)-dione Derivatives <b>20a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ammonium hydroxide, CH<sub>2</sub>Cl<sub>2</sub>, 0 °C, 2 h, 92%; (b) <i>tert</i>-butyl(3-aminophenyl)carbamate, DIPEA, 2-propanol, 40 °C, 5 h, 84%; (c) arylamine, trifluoroacetic acid, 2-propanol, reflux, overnight, 67%; (d) 1,1′-carbonyldiimidazole, K<sub>2</sub>CO<sub>3</sub>, dry THF, reflux, overnight, 60%; (e) haloalkane, Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt, overnight, 55–61%; (f) trifluoroacetic acid, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h, 78–82%; (g) acrylyl chloride, NMP/CH<sub>3</sub>CN, 0 °C to rt, overnight, 37–49%.</p></p></figure><figure data-id="fig2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) The 2D drawings of compound <b>5</b> and <b>7</b>. (B) The overlaid docked poses of <b>5</b> (shown in orange sticks) and <b>7</b> (shown in blue sticks). The gatekeeper, hinge and covalent regions of both wild-type (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J">4G5J</a>) and double-mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) EGFR kinases are displayed in yellow sticks and cyan sticks, respectively. (C) The sliced view of the predicted binding mode of <b>14a</b>. The docked pose of compound <b>14a</b> is in yellow sticks. The key residues Met793 and Met790 are shown in cyan sticks. The rest of the protein is demonstrated in a surface mode (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (D) The 2D interactions of the new scaffold to show strategies of structural modifications. (E) The docked pose of compound <b>20c</b>. The protein (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) is shown in a blue cartoon, and the key residues are shown in blue sticks. Key H-bond and VDW interactions are measured by distances. (F) The docked pose of compound <b>20f</b>. The compound <b>20f</b> is in orange sticks. The mesh surface is shown to display the shape of the binding site and the S2 pocket. The key residues in the covalent, hinge, and S2-pocket regions of both wild-type (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP">2RGP</a>) and double-mutant (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W2S">3W2S</a>) EGFR kinases are displayed in cyan sticks and green sticks, respectively</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Inhibitory effects of compound <b>20g</b> for EGFR and downstream signaling transduction in H1975 cells (A) and A431 cells (B).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Target duration in vitro. NCI-H1975 cells were treated with <b>20g</b> (A) or compound <b>6</b> (B) for 2 h, then washed with PBS for three times. Target inhibition at different time points was detected by Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/medium/jm-2018-00346h_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Preliminary in vivo antitumor efficiency study of compound <b>20g</b> (50 mg/kg/day) against H1975 and A431 NSCLC xenograft mouse models. (A) H1975 xenograft mouse model (<i>n</i> = 6) tumor volumes and (C) body weights. (B) A431 xenograft mouse model (<i>n</i> = 6) tumor volumes and (D) body weights were recorded every 2–3 days. All values expressed as mean ± SEM (*) <i>p</i> < 0.05 or (***) <i>p</i> < 0.001 (Student’s <i>t</i> test) vs the vehicle group.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2018/jmcmar.2018.61.issue-13/acs.jmedchem.8b00346/20180706/images/large/jm-2018-00346h_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b00346&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i58">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84088" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84088" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 34 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brawley, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Cancer statistics, 2011</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">212</span>– <span class="NLM_lpage">236</span>, <span class="refDoi"> DOI: 10.3322/caac.20121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.3322%2Fcaac.20121" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=21685461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BC3MnkslKhsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2011&pages=212-236&author=R.+Siegelauthor=E.+Wardauthor=O.+Brawleyauthor=A.+Jemal&title=Cancer+statistics%2C+2011&doi=10.3322%2Fcaac.20121"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths</span></div><div class="casAuthors">Siegel Rebecca; Ward Elizabeth; Brawley Otis; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">212-36</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths expected in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival based on incidence data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries and mortality data from the National Center for Health Statistics.  A total of 1,596,670 new cancer cases and 571,950 deaths from cancer are projected to occur in the United States in 2011.  Overall cancer incidence rates were stable in men in the most recent time period after decreasing by 1.9% per year from 2001 to 2005; in women, incidence rates have been declining by 0.6% annually since 1998.  Overall cancer death rates decreased in all racial/ethnic groups in both men and women from 1998 through 2007, with the exception of American Indian/Alaska Native women, in whom rates were stable.  African American and Hispanic men showed the largest annual decreases in cancer death rates during this time period (2.6% and 2.5%, respectively).  Lung cancer death rates showed a significant decline in women after continuously increasing since the 1930s.  The reduction in the overall cancer death rates since 1990 in men and 1991 in women translates to the avoidance of about 898,000 deaths from cancer.  However, this progress has not benefitted all segments of the population equally; cancer death rates for individuals with the least education are more than twice those of the most educated.  The elimination of educational and racial disparities could potentially have avoided about 37% (60,370) of the premature cancer deaths among individuals aged 25 to 64 years in 2007 alone.  Further progress can be accelerated by applying existing cancer control knowledge across all segments of the population with an emphasis on those groups in the lowest socioeconomic bracket.  CA Cancer J Clin 2011. © 2011 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSV6umkq5UbgGlSCSgBhwJFfW6udTcc2ea_zl08Z3_Garntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MnkslKhsg%253D%253D&md5=7fbc8af4359e652a7dd1048a031ffcc3</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.20121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.20121%26sid%3Dliteratum%253Aachs%26aulast%3DSiegel%26aufirst%3DR.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DBrawley%26aufirst%3DO.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DCancer%2520statistics%252C%25202011%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2011%26volume%3D61%26spage%3D212%26epage%3D236%26doi%3D10.3322%2Fcaac.20121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sliwkowski, M. X.</span></span> <span> </span><span class="NLM_article-title">Untangling the ErbB signalling network</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">137</span>, <span class="refDoi"> DOI: 10.1038/35052073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2F35052073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=11252954" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2001&pages=127-137&author=Y.+Yardenauthor=M.+X.+Sliwkowski&title=Untangling+the+ErbB+signalling+network&doi=10.1038%2F35052073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Untangling the ErbB signalling network</span></div><div class="casAuthors">Yarden, Yosef; Sliwkowski, Mark X.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">127-137</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review, with 112 refs.  When epidermal growth factor and its relatives bind the ErbB family of receptors, they trigger a rich network of signaling pathways, culminating in responses ranging from cell division to death, motility to adhesion.  The network is often dysregulated in cancer and lends credence to the mantra that mol. understanding yields clin. benefit: over 25,000 women with breast cancer have now been treated with Herceptin, a recombinant antibody designed to block the receptor ErbB2.  Likewise, small-mol. enzyme inhibitors and monoclonal antibodies to ErbB1 are in advanced phases of clin. testing.  What can this pathway teach us about translating basic science into clin. use.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovhWL1HObvNrVg90H21EOLACvtfcHk0li0O1XEXEukVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXivVWnt7k%253D&md5=1561a9666f77fce888be821399870cd6</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2F35052073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F35052073%26sid%3Dliteratum%253Aachs%26aulast%3DYarden%26aufirst%3DY.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26atitle%3DUntangling%2520the%2520ErbB%2520signalling%2520network%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2001%26volume%3D2%26spage%3D127%26epage%3D137%26doi%3D10.1038%2F35052073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oda, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuoka, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funahashi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitano, H.</span></span> <span> </span><span class="NLM_article-title">A comprehensive pathway map of epidermal growth factor receptor signaling</span>. <i>Mol. Syst. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">2005.0010</span>, <span class="refDoi"> DOI: 10.1038/msb4100014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fmsb4100014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=16729045" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BD283psl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2005&pages=2005.0010&author=K.+Odaauthor=Y.+Matsuokaauthor=A.+Funahashiauthor=H.+Kitano&title=A+comprehensive+pathway+map+of+epidermal+growth+factor+receptor+signaling&doi=10.1038%2Fmsb4100014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">A comprehensive pathway map of epidermal growth factor receptor signaling</span></div><div class="casAuthors">Oda Kanae; Matsuoka Yukiko; Funahashi Akira; Kitano Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Molecular systems biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2005.0010</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) signaling pathway is one of the most important pathways that regulate growth, survival, proliferation, and differentiation in mammalian cells.  Reflecting this importance, it is one of the best-investigated signaling systems, both experimentally and computationally, and several computational models have been developed for dynamic analysis.  A map of molecular interactions of the EGFR signaling system is a valuable resource for research in this area.  In this paper, we present a comprehensive pathway map of EGFR signaling and other related pathways.  The map reveals that the overall architecture of the pathway is a bow-tie (or hourglass) structure with several feedback loops.  The map is created using CellDesigner software that enables us to graphically represent interactions using a well-defined and consistent graphical notation, and to store it in Systems Biology Markup Language (SBML).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTWCPwXSabaPEmhnSqMnvzDfW6udTcc2eYdxxaL6NnaJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD283psl2gsg%253D%253D&md5=e5e5109cab456b01027f8bc160c4cbc9</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fmsb4100014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fmsb4100014%26sid%3Dliteratum%253Aachs%26aulast%3DOda%26aufirst%3DK.%26aulast%3DMatsuoka%26aufirst%3DY.%26aulast%3DFunahashi%26aufirst%3DA.%26aulast%3DKitano%26aufirst%3DH.%26atitle%3DA%2520comprehensive%2520pathway%2520map%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520signaling%26jtitle%3DMol.%2520Syst.%2520Biol.%26date%3D2005%26volume%3D1%26spage%3D2005.0010%26doi%3D10.1038%2Fmsb4100014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Peters, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adjei, A. A.</span></span> <span> </span><span class="NLM_article-title">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: comparative pharmacokinetics and drug–drug interactions</span>. <i>Cancer Treat. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">917</span>– <span class="NLM_lpage">926</span>, <span class="refDoi"> DOI: 10.1016/j.ctrv.2014.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2Fj.ctrv.2014.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=25027951" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2014&pages=917-926&author=S.+Petersauthor=S.+Zimmermannauthor=A.+A.+Adjei&title=Oral+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitors+for+the+treatment+of+non-small+cell+lung+cancer%3A+comparative+pharmacokinetics+and+drug%E2%80%93drug+interactions&doi=10.1016%2Fj.ctrv.2014.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug-drug interactions</span></div><div class="casAuthors">Peters, Solange; Zimmermann, Stefan; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Treatment Reviews</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">917-926</span>CODEN:
                <span class="NLM_cas:coden">CTREDJ</span>;
        ISSN:<span class="NLM_cas:issn">0305-7372</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The development of orally active small mol. inhibitors of the epidermal growth factor receptor (EGFR) has led to new treatment options for non-small cell lung cancer (NSCLC).  Patients with activating mutations of the EGFR gene show sensitivity to, and clin. benefit from, treatment with EGFR tyrosine kinase inhibitors (EGFR-TKls).  First generation reversible ATP-competitive EGFR-TKls, gefitinib and erlotinib, are effective as first, second-line or maintenance therapy.  Despite initial benefit, most patients develop resistance within a year, 50-60% of cases being related to the appearance of a T790M gatekeeper mutation.  Newer, irreversible EGFR-TKls - afatinib and dacomitinib - covalently bind to and inhibit multiple receptors in the ErbB family (EGFR, HER2 and HER4).  These agents have been mainly evaluated for first-line treatment but also in the setting of acquired resistance to first-generation EGFR-TKls.  Afatinib is the first ErbB family blocker approved for patients with NSCLC with activating EGFR mutations; dacomitinib is in late stage clin. development.  Mutant-selective EGFR inhibitors (AZD9291, CO-1686, HM61713) that specifically target the T790M resistance mutation are in early development.  The EGFR-TKIs differ in their spectrum of target kinases, reversibility of binding to EGFR receptor, pharmacokinetics and potential for drug-drug interactions, as discussed in this review.  For the clinician, these differences are relevant in the setting of polymedicated patients with NSCLC, as well as from the perspective of innovative anticancer drug combination strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLFElQmV4ha7Vg90H21EOLACvtfcHk0liVwNSiW0Njkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFGmtbrP&md5=31253f81e203aa012a5d87ad29ff6fc3</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ctrv.2014.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ctrv.2014.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DS.%26aulast%3DZimmermann%26aufirst%3DS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DOral%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520non-small%2520cell%2520lung%2520cancer%253A%2520comparative%2520pharmacokinetics%2520and%2520drug%25E2%2580%2593drug%2520interactions%26jtitle%3DCancer%2520Treat.%2520Rev.%26date%3D2014%26volume%3D40%26spage%3D917%26epage%3D926%26doi%3D10.1016%2Fj.ctrv.2014.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Williams, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGuinn, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morse, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lostritto, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baird, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">United states food and drug administration drug approval summary: gefitinib (ZD1839; Iressa) tablets</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1212</span>– <span class="NLM_lpage">1218</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-03-0564</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F1078-0432.CCR-03-0564" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=14977817" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsVCqt7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2004&pages=1212-1218&author=M.+H.+Cohenauthor=G.+A.+Williamsauthor=R.+Sridharaauthor=G.+Chenauthor=W.+D.+McGuinnauthor=D.+Morseauthor=S.+Abrahamauthor=A.+Rahmanauthor=C.+Liangauthor=R.+Lostrittoauthor=A.+Bairdauthor=R.+Pazdur&title=United+states+food+and+drug+administration+drug+approval+summary%3A+gefitinib+%28ZD1839%3B+Iressa%29+tablets&doi=10.1158%2F1078-0432.CCR-03-0564"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">United States Food and Drug Administration Drug Approval Summary: Gefitinib (ZD1839; Iressa) Tablets</span></div><div class="casAuthors">Cohen, Martin H.; Williams, Grant A.; Sridhara, Rajeshwari; Chen, Gang; McGuinn, W. David, Jr.; Morse, David; Abraham, Sophia; Rahman, Atiqur; Liang, Chenyi; Lostritto, Richard; Baird, Amy; Pazdur, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1212-1218</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.  Information provided in this summary includes chem. manufg. and controls, clin. pharmacol., and clin. trial efficacy and safety results.  Gefitinib is an anilinoquinazoline compd. with the chem. name 4-quinazolinamine,N-(3-chloro-4-flurophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy].  It has the mol. formula C22H24ClFN4O3.  Gefitinib is often referred to as a "specific" or "selective" inhibitor of epidermal growth factor receptor.  Studies demonstrate, however, that gefitinib inhibits the activity of other intracellular transmembrane tyrosine-specific protein kinases at concns. similar to those at which it inhibits the epidermal growth factor signal.  Maximum plasma concns. resulting from clin. relevant doses are 0.5-1 μM or more, well within the IC50 values of several tyrosine kinases.  No clin. studies have been performed that demonstrate a correlation between epidermal growth factor receptor expression and response to gefitinib.  Gefitinib is 60% available after oral administration and is widely distributed throughout the body.  Gefitinib is extensively metabolized in the liver by cytochrome P 450 3A4 enzyme.  Over a 10-day period, approx. 86% of an orally administered radioactive dose is recovered in the feces, with <4% of the dose in the urine.  After daily oral administration, steady-state plasma levels are reached in 10 days and are 2-fold higher than those achieved after single doses.  Gefitinib effectiveness was demonstrated in a randomized, double-blind, Phase II, multicenter trial comparing two oral doses of gefitinib (250 vs. 500 mg/day).  A total of 216 patients were enrolled.  The 142 patients who were refractory to or intolerant of a platinum and docetaxel comprised the evaluable population for the efficacy anal.  A partial tumor response occurred in 14% (9 of 66) of patients receiving 250 mg/day gefitinib and in 8% (6 of 76) of patients receiving 500 mg/day gefitinib.  The overall objective response rate (RR) for both doses combined was 10.6% (15 of 142 patients; 95% confidence interval, 6.0-16.8%).  Responses were more frequent in females and in nonsmokers.  The median duration of response was 7.0 mo (range, 4.6-18.6+ months).  Other submitted data included the results of two large trials conducted in chemotherapy-naive, stage III and IV non-small cell lung cancer patients.  Patients were randomized to receive gefitinib (250 or 500 mg daily) or placebo, in combination with either gemcitabine plus cisplatin (n = 1093) or carboplatin plus paclitaxel (n = 1037).  Results from this study showed no benefit (RR, time to progression, or survival) from adding gefitinib to chemotherapy.  Consequently, gefinitib is only recommended for use as monotherapy.  Common adverse events assocd. with gefitinib treatment included diarrhea, rash, acne, dry skin, nausea, and vomiting.  Interstitial lung disease has been obsd. in patients receiving gefitinib.  Worldwide, the incidence of interstitial lung disease was about 1% (2% in the Japanese post-marketing experience and about 0.3% in a United States expanded access program).  Approx. one-third of the cases have been fatal.  Gefitinib was approved under accelerated approval regulations on the basis of a surrogate end point, RR.  No controlled gefitinib trials, to date, demonstrate a clin. benefit, such as improvement in disease-related symptoms or increased survival.  Accelerated approval regulations require the sponsor to conduct addnl. studies to verify that gefitinib therapy produces such benefit.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0OwDrydcaSLVg90H21EOLACvtfcHk0liVwNSiW0Njkw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsVCqt7k%253D&md5=5dd1d0276553d177875e35357b51e6d9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-03-0564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-03-0564%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DWilliams%26aufirst%3DG.%2BA.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DMcGuinn%26aufirst%3DW.%2BD.%26aulast%3DMorse%26aufirst%3DD.%26aulast%3DAbraham%26aufirst%3DS.%26aulast%3DRahman%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DLostritto%26aufirst%3DR.%26aulast%3DBaird%26aufirst%3DA.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DUnited%2520states%2520food%2520and%2520drug%2520administration%2520drug%2520approval%2520summary%253A%2520gefitinib%2520%2528ZD1839%253B%2520Iressa%2529%2520tablets%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2004%26volume%3D10%26spage%3D1212%26epage%3D1218%26doi%3D10.1158%2F1078-0432.CCR-03-0564" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sridhara, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazdur, R.</span></span> <span> </span><span class="NLM_article-title">FDA drug approval summary: erlotinib (Tarceva®) tablets</span>. <i>Oncologist</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">461</span>– <span class="NLM_lpage">466</span>, <span class="refDoi"> DOI: 10.1634/theoncologist.10-7-461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1634%2Ftheoncologist.10-7-461" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=461-466&author=M.+H.+Cohenauthor=J.+R.+Johnsonauthor=Y.-F.+Chenauthor=R.+Sridharaauthor=R.+Pazdur&title=FDA+drug+approval+summary%3A+erlotinib+%28Tarceva%C2%AE%29+tablets&doi=10.1634%2Ftheoncologist.10-7-461"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.10-7-461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.10-7-461%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DM.%2BH.%26aulast%3DJohnson%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DY.-F.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520drug%2520approval%2520summary%253A%2520erlotinib%2520%2528Tarceva%25C2%25AE%2529%2520tablets%26jtitle%3DOncologist%26date%3D2005%26volume%3D10%26spage%3D461%26epage%3D466%26doi%3D10.1634%2Ftheoncologist.10-7-461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cataldo, V. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibbons, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pérez-Soler, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quintás-Cardama, A.</span></span> <span> </span><span class="NLM_article-title">Treatment of non–small-cell lung cancer with erlotinib or gefitinib</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>364</i></span>,  <span class="NLM_fpage">947</span>– <span class="NLM_lpage">955</span>, <span class="refDoi"> DOI: 10.1056/NEJMct0807960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1056%2FNEJMct0807960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=21388312" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=947-955&author=V.+D.+Cataldoauthor=D.+L.+Gibbonsauthor=R.+P%C3%A9rez-Solerauthor=A.+Quint%C3%A1s-Cardama&title=Treatment+of+non%E2%80%93small-cell+lung+cancer+with+erlotinib+or+gefitinib&doi=10.1056%2FNEJMct0807960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment of non-small-cell lung cancer with erlotinib or gefitinib</span></div><div class="casAuthors">Cataldo, Vince D.; Gibbons, Don L.; Perez-Soler, Roman; Quintas-Cardama, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">947-955</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGraDIxHbNbHr7Vg90H21EOLACvtfcHk0lgLTpCQmv8MYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjtFentbg%253D&md5=5030feb97e5b6b09e3e11d6946cde577</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1056%2FNEJMct0807960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMct0807960%26sid%3Dliteratum%253Aachs%26aulast%3DCataldo%26aufirst%3DV.%2BD.%26aulast%3DGibbons%26aufirst%3DD.%2BL.%26aulast%3DP%25C3%25A9rez-Soler%26aufirst%3DR.%26aulast%3DQuint%25C3%25A1s-Cardama%26aufirst%3DA.%26atitle%3DTreatment%2520of%2520non%25E2%2580%2593small-cell%2520lung%2520cancer%2520with%2520erlotinib%2520or%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D947%26epage%3D955%26doi%3D10.1056%2FNEJMct0807960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mitsudomi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morita, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yatabe, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negoro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okamoto, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsurutani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Satouchi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tada, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirashima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katakami, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshioka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shibata, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kudoh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimizu, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toyooka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuoka, M.</span></span> <span> </span><span class="NLM_article-title">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">121</span>– <span class="NLM_lpage">128</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(09)70364-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2FS1470-2045%2809%2970364-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=20022809" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=121-128&author=T.+Mitsudomiauthor=S.+Moritaauthor=Y.+Yatabeauthor=S.+Negoroauthor=I.+Okamotoauthor=J.+Tsurutaniauthor=T.+Setoauthor=M.+Satouchiauthor=H.+Tadaauthor=T.+Hirashimaauthor=K.+Asamiauthor=N.+Katakamiauthor=M.+Takadaauthor=H.+Yoshiokaauthor=K.+Shibataauthor=S.+Kudohauthor=E.+Shimizuauthor=H.+Saitoauthor=S.+Toyookaauthor=K.+Nakagawaauthor=M.+Fukuoka&title=Gefitinib+versus+cisplatin+plus+docetaxel+in+patients+with+non-small-cell+lung+cancer+harbouring+mutations+of+the+epidermal+growth+factor+receptor+%28WJTOG3405%29%3A+an+open+label%2C+randomised+phase+3+trial&doi=10.1016%2FS1470-2045%2809%2970364-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</span></div><div class="casAuthors">Mitsudomi, Tetsuya; Morita, Satoshi; Yatabe, Yasushi; Negoro, Shunichi; Okamoto, Isamu; Tsurutani, Junji; Seto, Takashi; Satouchi, Miyako; Tada, Hirohito; Hirashima, Tomonori; Asami, Kazuhiro; Katakami, Nobuyuki; Takada, Minoru; Yoshioka, Hiroshige; Shibata, Kazuhiko; Kudoh, Shinzoh; Shimizu, Eiji; Saito, Hiroshi; Toyooka, Shinichi; Nakagawa, Kazuhiko; Fukuoka, Masahiro</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">121-128</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Patients with non-small-cell lung cancer harboring mutations in the epidermal growth factor receptor (EGFR) gene respond well to the EGFR-specific tyrosine kinase inhibitor gefitinib.  However, whether gefitinib is better than std. platinum doublet chemotherapy in patients selected by EGFR mutation is uncertain.  We did an open label, phase 3 study (WJTOG3405) with recruitment between March 31, 2006, and June 22, 2009, at 36 centers in Japan. 177 chemotherapy-naive patients aged 75 years or younger and diagnosed with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harboring EGFR mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, using a minimization technique, to receive either gefitinib (250 mg/day orally; n=88) or cisplatin (80 mg/m2, i.v.) plus docetaxel (60 mg/m2, i.v.; n=89), administered every 21 days for three to six cycles.  The primary endpoint was progression-free survival.  Survival anal. was done with the modified intention-to-treat population.  This study is registered with UMIN (University Hospital Medical Information Network in Japan), no. 000000539.  Five patients were excluded (two patients were found to have thyroid and colon cancer after randomization, one patient had an exon 18 mutation, one patient had insufficient consent, and one patient showed acute allergic reaction to docetaxel).  Thus, 172 patients (86 in each group) were included in the survival analyses.  The gefitinib group had significantly longer progression-free survival compared with the cisplatin plus docetaxel group, with a median progression-free survival time of 9.2 mo (95% CI 8.0-13.9) vs. 6.3 mo (5.8-7.8; HR 0.489, 95% CI 0.336-0.710, log-rank p<0.0001).  Myelosuppression, alopecia, and fatigue were more frequent in the cisplatin plus docetaxel group, but skin toxicity, liver dysfunction, and diarrhea were more frequent in the gefitinib group.  Two patients in the gefitinib group developed interstitial lung disease (incidence 2.3%), one of whom died.  Patients with lung cancer who are selected by EGFR mutations have longer progression-free survival if they are treated with gefitinib than if they are treated with cisplatin plus docetaxel.  Funding: West Japan Oncol. Group (WJOG): a non-profit organization supported by unrestricted donations from several pharmaceutical companies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKXuDlK2x9o7Vg90H21EOLACvtfcHk0liZjJYA6gGtAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlGgtbo%253D&md5=5856ce118d00919627e3f21525abe453</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2809%2970364-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252809%252970364-X%26sid%3Dliteratum%253Aachs%26aulast%3DMitsudomi%26aufirst%3DT.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DYatabe%26aufirst%3DY.%26aulast%3DNegoro%26aufirst%3DS.%26aulast%3DOkamoto%26aufirst%3DI.%26aulast%3DTsurutani%26aufirst%3DJ.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DSatouchi%26aufirst%3DM.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DHirashima%26aufirst%3DT.%26aulast%3DAsami%26aufirst%3DK.%26aulast%3DKatakami%26aufirst%3DN.%26aulast%3DTakada%26aufirst%3DM.%26aulast%3DYoshioka%26aufirst%3DH.%26aulast%3DShibata%26aufirst%3DK.%26aulast%3DKudoh%26aufirst%3DS.%26aulast%3DShimizu%26aufirst%3DE.%26aulast%3DSaito%26aufirst%3DH.%26aulast%3DToyooka%26aufirst%3DS.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DFukuoka%26aufirst%3DM.%26atitle%3DGefitinib%2520versus%2520cisplatin%2520plus%2520docetaxel%2520in%2520patients%2520with%2520non-small-cell%2520lung%2520cancer%2520harbouring%2520mutations%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528WJTOG3405%2529%253A%2520an%2520open%2520label%252C%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D121%26epage%3D128%26doi%3D10.1016%2FS1470-2045%2809%2970364-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rosell, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carcereny, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gervais, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vergnenegre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Massuti, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmero, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Gomez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cobo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrido, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Longo, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Marinis, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bover, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Illiano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dansin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Castro, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milella, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reguart, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altavilla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provencio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moreno, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terrasa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muñoz-Langa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valdivia, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isla, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Domine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molinier, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazieres, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baize, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garcia-Campelo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robinet, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez-Abreu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez-Vivanco, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gebbia, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrera-Delgado, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bombaron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernabe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bearz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Artal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortesi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rolfo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez-Ronco, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drozdowskyj, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Queralt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Aguirre, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramirez, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanchez, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taron, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paz-Ares, L.</span></span> <span> </span><span class="NLM_article-title">Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">239</span>– <span class="NLM_lpage">246</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(11)70393-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2FS1470-2045%2811%2970393-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=22285168" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=239-246&author=R.+Rosellauthor=E.+Carcerenyauthor=R.+Gervaisauthor=A.+Vergnenegreauthor=B.+Massutiauthor=E.+Felipauthor=R.+Palmeroauthor=R.+Garcia-Gomezauthor=C.+Pallaresauthor=J.+M.+Sanchezauthor=R.+Portaauthor=M.+Coboauthor=P.+Garridoauthor=F.+Longoauthor=T.+Moranauthor=A.+Insaauthor=F.+De+Marinisauthor=R.+Correauthor=I.+Boverauthor=A.+Illianoauthor=E.+Dansinauthor=J.+de+Castroauthor=M.+Milellaauthor=N.+Reguartauthor=G.+Altavillaauthor=U.+Jimenezauthor=M.+Provencioauthor=M.+A.+Morenoauthor=J.+Terrasaauthor=J.+Mu%C3%B1oz-Langaauthor=J.+Valdiviaauthor=D.+Islaauthor=M.+Domineauthor=O.+Molinierauthor=J.+Mazieresauthor=N.+Baizeauthor=R.+Garcia-Campeloauthor=G.+Robinetauthor=D.+Rodriguez-Abreuauthor=G.+Lopez-Vivancoauthor=V.+Gebbiaauthor=L.+Ferrera-Delgadoauthor=P.+Bombaronauthor=R.+Bernabeauthor=A.+Bearzauthor=A.+Artalauthor=E.+Cortesiauthor=C.+Rolfoauthor=M.+Sanchez-Roncoauthor=A.+Drozdowskyjauthor=C.+Queraltauthor=I.+de+Aguirreauthor=J.+L.+Ramirezauthor=J.+J.+Sanchezauthor=M.+A.+Molinaauthor=M.+Taronauthor=L.+Paz-Ares&title=Erlotinib+versus+standard+chemotherapy+as+first-line+treatment+for+european+patients+with+advanced+EGFR+mutation-positive+non-small-cell+lung+cancer+%28EURTAC%29%3A+a+multicentre%2C+open-label%2C+randomised+phase+3+trial&doi=10.1016%2FS1470-2045%2811%2970393-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial</span></div><div class="casAuthors">Rosell, Rafael; Carcereny, Enric; Gervais, Radj; Vergnenegre, Alain; Massuti, Bartomeu; Felip, Enriqueta; Palmero, Ramon; Garcia-Gomez, Ramon; Pallares, Cinta; Sanchez, Jose Miguel; Porta, Rut; Cobo, Manuel; Garrido, Pilar; Longo, Flavia; Moran, Teresa; Insa, Amelia; De Marinis, Filippo; Corre, Romain; Bover, Isabel; Illiano, Alfonso; Dansin, Eric; de Castro, Javier; Milella, Michele; Reguart, Noemi; Altavilla, Giuseppe; Jimenez, Ulpiano; Provencio, Mariano; Moreno, Miguel Angel; Terrasa, Josefa; Munoz-Langa, Jose; Valdivia, Javier; Isla, Dolores; Domine, Manuel; Molinier, Olivier; Mazieres, Julien; Baize, Nathalie; Garcia-Campelo, Rosario; Robinet, Gilles; Rodriguez-Abreu, Delvys; Lopez-Vivanco, Guillermo; Gebbia, Vittorio; Ferrera-Delgado, Lioba; Bombaron, Pierre; Bernabe, Reyes; Bearz, Alessandra; Artal, Angel; Cortesi, Enrico; Rolfo, Christian; Sanchez-Ronco, Maria; Drozdowskyj, Ana; Queralt, Cristina; de Aguirre, Itziar; Ramirez, Jose Luis; Sanchez, Jose Javier; Molina, Miguel Angel; Taron, Miquel; Paz-Ares, Luis</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">239-246</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations.  We aimed to assess the safety and efficacy of erlotinib compared with std. chemotherapy for first-line treatment of European patients with advanced EGFR-mutation pos. NSCLC.  Methods: We undertook the open-label, randomized phase 3 EURTAC trial at 42 hospitals in France, Italy, and Spain.  Eligible participants were adults (>18 years) with NSCLC and EGFR mutations (exon 19 deletion or L858R mutation in exon 21) with no history of chemotherapy for metastatic disease (neoadjuvant or adjuvant chemotherapy ending ≥6 mo before study entry was allowed).  We randomly allocated participants (1:1) according to a computer-generated allocation schedule to receive oral erlotinib 150 mg per day or 3 wk cycles of std. i.v. chemotherapy of cisplatin 75 mg/m2 on day 1 plus docetaxel (75 mg/m2 on day 1) or gemcitabine (1250 mg/m2 on days 1 and 8).  Carboplatin (AUC 6 with docetaxel 75 mg/m2 or AUC 5 with gemcitabine 1000 mg/m2) was allowed in patients unable to have cisplatin.  Patients were stratified by EGFR mutation type and Eastern Cooperative Oncol. Group performance status (0 vs 1 vs 2).  The primary endpoint was progression-free survival (PFS) in the intention-to-treat population.  We assessed safety in all patients who received study drug (≥1 dose).  This study is registered with ClinicalTrials.gov, no. NCT00446225.  Findings: Between Feb 15, 2007, and Jan 4, 2011, 174 patients with EGFR mutations were enrolled.  One patient received treatment before randomization and was thus withdrawn from the study; of the remaining patients, 86 were randomly assigned to receive erlotinib and 87 to receive std. chemotherapy.  The preplanned interim anal. showed that the study met its primary endpoint; enrollment was halted, and full evaluation of the results was recommended.  At data cutoff (Jan 26, 2011), median PFS was 9·7 mo (95% CI 8·4-12·3) in the erlotinib group, compared with 5·2 mo (4·5-5·8) in the std. chemotherapy group (hazard ratio 0·37, 95% CI 0·25-0·54; p<0·0001).  Main grade 3 or 4 toxicities were rash (11 [13%] of 84 patients given erlotinib vs none of 82 patients in the chemotherapy group), neutropenia (none vs 18 [22%]), anemia (one [1%] vs three [4%]), and increased amino-transferase concns. (two [2%] vs 0).  Five (6%) patients on erlotinib had treatment-related severe adverse events compared with 16 patients (20%) on chemotherapy.  One patient in the erlotinib group and two in the std. chemotherapy group died from treatment-related causes.  Interpretation: Our findings strengthen the rationale for routine baseline tissue-based assessment of EGFR mutations in patients with NSCLC and for treatment of mutation-pos. patients with EGFR tyrosine-kinase inhibitors.  Funding: Spanish Lung Cancer Group, Roche Farma, Hoffmann-La Roche, and Red Tematica de Investigacion Cooperativa en Cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFHsqWOF3EU7Vg90H21EOLACvtfcHk0liZjJYA6gGtAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjsVCgsbk%253D&md5=9b7c83e16707fba2bc2f4a878effbfb3</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2811%2970393-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252811%252970393-X%26sid%3Dliteratum%253Aachs%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DCarcereny%26aufirst%3DE.%26aulast%3DGervais%26aufirst%3DR.%26aulast%3DVergnenegre%26aufirst%3DA.%26aulast%3DMassuti%26aufirst%3DB.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DPalmero%26aufirst%3DR.%26aulast%3DGarcia-Gomez%26aufirst%3DR.%26aulast%3DPallares%26aufirst%3DC.%26aulast%3DSanchez%26aufirst%3DJ.%2BM.%26aulast%3DPorta%26aufirst%3DR.%26aulast%3DCobo%26aufirst%3DM.%26aulast%3DGarrido%26aufirst%3DP.%26aulast%3DLongo%26aufirst%3DF.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DInsa%26aufirst%3DA.%26aulast%3DDe%2BMarinis%26aufirst%3DF.%26aulast%3DCorre%26aufirst%3DR.%26aulast%3DBover%26aufirst%3DI.%26aulast%3DIlliano%26aufirst%3DA.%26aulast%3DDansin%26aufirst%3DE.%26aulast%3Dde%2BCastro%26aufirst%3DJ.%26aulast%3DMilella%26aufirst%3DM.%26aulast%3DReguart%26aufirst%3DN.%26aulast%3DAltavilla%26aufirst%3DG.%26aulast%3DJimenez%26aufirst%3DU.%26aulast%3DProvencio%26aufirst%3DM.%26aulast%3DMoreno%26aufirst%3DM.%2BA.%26aulast%3DTerrasa%26aufirst%3DJ.%26aulast%3DMu%25C3%25B1oz-Langa%26aufirst%3DJ.%26aulast%3DValdivia%26aufirst%3DJ.%26aulast%3DIsla%26aufirst%3DD.%26aulast%3DDomine%26aufirst%3DM.%26aulast%3DMolinier%26aufirst%3DO.%26aulast%3DMazieres%26aufirst%3DJ.%26aulast%3DBaize%26aufirst%3DN.%26aulast%3DGarcia-Campelo%26aufirst%3DR.%26aulast%3DRobinet%26aufirst%3DG.%26aulast%3DRodriguez-Abreu%26aufirst%3DD.%26aulast%3DLopez-Vivanco%26aufirst%3DG.%26aulast%3DGebbia%26aufirst%3DV.%26aulast%3DFerrera-Delgado%26aufirst%3DL.%26aulast%3DBombaron%26aufirst%3DP.%26aulast%3DBernabe%26aufirst%3DR.%26aulast%3DBearz%26aufirst%3DA.%26aulast%3DArtal%26aufirst%3DA.%26aulast%3DCortesi%26aufirst%3DE.%26aulast%3DRolfo%26aufirst%3DC.%26aulast%3DSanchez-Ronco%26aufirst%3DM.%26aulast%3DDrozdowskyj%26aufirst%3DA.%26aulast%3DQueralt%26aufirst%3DC.%26aulast%3Dde%2BAguirre%26aufirst%3DI.%26aulast%3DRamirez%26aufirst%3DJ.%2BL.%26aulast%3DSanchez%26aufirst%3DJ.%2BJ.%26aulast%3DMolina%26aufirst%3DM.%2BA.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DPaz-Ares%26aufirst%3DL.%26atitle%3DErlotinib%2520versus%2520standard%2520chemotherapy%2520as%2520first-line%2520treatment%2520for%2520european%2520patients%2520with%2520advanced%2520EGFR%2520mutation-positive%2520non-small-cell%2520lung%2520cancer%2520%2528EURTAC%2529%253A%2520a%2520multicentre%252C%2520open-label%252C%2520randomised%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D239%26epage%3D246%26doi%3D10.1016%2FS1470-2045%2811%2970393-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lgEwoPdLooS7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rewcastle, G. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, O. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reyner, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lipka, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Showalter, H. D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. irreversible inhibitors of the epidermal growth factor receptor:  4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides bearing additional solubilizing functions</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">1380</span>– <span class="NLM_lpage">1397</span>, <span class="refDoi"> DOI: 10.1021/jm990482t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm990482t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2000&pages=1380-1397&author=J.+B.+Smaillauthor=G.+W.+Rewcastleauthor=J.+A.+Looauthor=K.+D.+Greisauthor=O.+H.+Chanauthor=E.+L.+Reynerauthor=E.+Lipkaauthor=H.+D.+H.+Showalterauthor=P.+W.+Vincentauthor=W.+L.+Elliottauthor=W.+A.+Denny&title=Tyrosine+kinase+inhibitors.+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor%3A%E2%80%89+4-%28phenylamino%29quinazoline-+and+4-%28phenylamino%29pyrido%5B3%2C2-d%5Dpyrimidine-6-acrylamides+bearing+additional+solubilizing+functions&doi=10.1021%2Fjm990482t"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm990482t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm990482t%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DRewcastle%26aufirst%3DG.%2BW.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DChan%26aufirst%3DO.%2BH.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLipka%26aufirst%3DE.%26aulast%3DShowalter%26aufirst%3DH.%2BD.%2BH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DElliott%26aufirst%3DW.%2BL.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%253A%25E2%2580%2589%25204-%2528phenylamino%2529quinazoline-%2520and%25204-%2528phenylamino%2529pyrido%255B3%252C2-d%255Dpyrimidine-6-acrylamides%2520bearing%2520additional%2520solubilizing%2520functions%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2000%26volume%3D43%26spage%3D1380%26epage%3D1397%26doi%3D10.1021%2Fjm990482t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek-Klumpers, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalak, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.-R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.-F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0lihqW2RptTkSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.-R.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.-F.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engelman, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zejnullahu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gale, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lifshits, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naumov, G. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gandhi, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">11924</span>– <span class="NLM_lpage">11932</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=18089823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+J%C3%A4nne&title=PF00299804%2C+an+irreversible+pan-ERBB+inhibitor%2C+is+effective+in+lung+cancer+models+with+EGFR+and+ERBB2+mutations+that+are+resistant+to+gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span></div><div class="casAuthors">Engelman, Jeffrey A.; Zejnullahu, Kreshnik; Gale, Christopher-Michael; Lifshits, Eugene; Gonzales, Andrea J.; Shimamura, Takeshi; Zhao, Feng; Vincent, Patrick W.; Naumov, George N.; Bradner, James E.; Althaus, Irene W.; Gandhi, Leena; Shapiro, Geoffrey I.; Nelson, James M.; Heymach, John V.; Meyerson, Matthew; Wong, Kwok-Kin; Jaenne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">11924-11932</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors gefitinib and erlotinib are effective treatments for a subset of non-small cell lung cancers.  In particular, cancers with specific EGFR-activating mutations seem to be the most sensitive to these agents.  However, despite their initial response, such cancers almost invariably develop resistance.  In 50% of such cancers, a secondary EGFR mutation, T790M, has been identified that renders gefitinib and erlotinib ineffective inhibitors of EGFR kinase activity.  Thus, there is a clin. need to develop novel EGFR inhibitors that can effectively inactivate T790M-contg. EGFR proteins.  In this study, we evaluate the effectiveness of a novel compd., PF00299804, an irreversible pan-ERBB inhibitor.  The results from these studies show that PF00299804 is a potent inhibitor of EGFR-activating mutations as well as the EGFR T790M resistance mutation both in vitro and in vivo.  Addnl., PF00299804 is a highly effective inhibitor of both the wild-type ERBB2 and the gefitinib-resistant oncogenic ERBB2 mutation identified in lung cancers.  These preclin. evaluations support further clin. development of PF00299804 for cancers with mutations and/or amplifications of ERBB family members. [Cancer Res 2007;67(24):11924-32].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq02Cx_x26RirVg90H21EOLACvtfcHk0lihqW2RptTkSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsVCjs7nL&md5=c210cf2fb3d1479df5915d317259696f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520irreversible%2520pan-ERBB%2520inhibitor%252C%2520is%2520effective%2520in%2520lung%2520cancer%2520models%2520with%2520EGFR%2520and%2520ERBB2%2520mutations%2520that%2520are%2520resistant%2520to%2520gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4702</span>– <span class="NLM_lpage">4711</span>, <span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0lihqW2RptTkSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+Dungoauthor=G.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0ljlsEbKtunFhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%26aulast%3DKeating%26aufirst%3DG.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsh, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, W.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heo, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crino, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, E.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, T.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahidi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cong, X. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorence, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. C.-H.</span></span> <span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-lung 1): a phase 2b/3 randomised trial</span>. <i>Lancet Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">528</span>– <span class="NLM_lpage">538</span>, <span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.-M.+Chenauthor=K.+Parkauthor=S.-W.+Kimauthor=C.+Zhouauthor=W.-C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.-H.+Tanauthor=T.-Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.-H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0ljlsEbKtunFhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-M.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liZJrLvW6QW9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0liZJrLvW6QW9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tjin
Tham Sjin, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Medikonda, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1468</span>– <span class="NLM_lpage">1479</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0966</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F1535-7163.MCT-13-0966" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=24723450" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=1468-1479&author=R.+Tjin%0ATham+Sjinauthor=K.+Leeauthor=A.+O.+Walterauthor=A.+Dubrovskiyauthor=M.+Sheetsauthor=T.+S.+Martinauthor=M.+T.+Labenskiauthor=Z.+Zhuauthor=R.+Testerauthor=R.+Karpauthor=A.+Medikondaauthor=P.+Chaturvediauthor=Y.+Renauthor=H.+Haringsmaauthor=J.+Etterauthor=M.+Raponiauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=D.+Niuauthor=M.+Nachtauthor=W.+F.+Westlinauthor=R.+C.+Petterauthor=A.+Allenauthor=J.+Singh&title=In+vitro+and+in+vivo+characterization+of+irreversible+mutant-selective+EGFR+inhibitors+that+are+wild-type+sparing&doi=10.1158%2F1535-7163.MCT-13-0966"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of irreversible mutant-selective EGFR inhibitors that are wild-type sparing</span></div><div class="casAuthors">Tjin Tham Sjin Robert; Lee Kwangho; Walter Annette O; Dubrovskiy Aleksandr; Sheets Michael; Martin Thia St; Labenski Matthew T; Zhu Zhendong; Tester Richland; Karp Russell; Medikonda Aravind; Chaturvedi Prasoon; Ren Yixuan; Haringsma Henry; Etter Jeff; Raponi Mitch; Simmons Andrew D; Harding Thomas C; Niu Deqiang; Nacht Mariana; Westlin William F; Petter Russell C; Allen Andrew; Singh Juswinder</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1468-79</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Patients with non-small cell lung carcinoma (NSCLC) with activating mutations in epidermal growth factor receptor (EGFR) initially respond well to the EGFR inhibitors erlotinib and gefitinib.  However, all patients relapse because of the emergence of drug-resistant mutations, with T790M mutations accounting for approximately 60% of all resistance.  Second-generation irreversible EGFR inhibitors are effective against T790M mutations in vitro, but retain affinity for wild-type EGFR (EGFR(WT)).  These inhibitors have not provided compelling clinical benefit in T790M-positive patients, apparently because of dose-limiting toxicities associated with inhibition of EGFR(WT).  Thus, there is an urgent clinical need for therapeutics that overcome T790M drug resistance while sparing EGFR(WT).  Here, we describe a lead optimization program that led to the discovery of four potent irreversible 2,4-diaminopyrimidine compounds that are EGFR mutant (EGFR(mut)) selective and have been designed to have low affinity for EGFR(WT).  Pharmacokinetic and pharmacodynamic studies in H1975 tumor-bearing mice showed that exposure was dose proportional resulting in dose-dependent EGFR modulation.  Importantly, evaluation of normal lung tissue from the same animals showed no inhibition of EGFR(WT).  Of all the compounds tested, compound 3 displayed the best efficacy in EGFR(L858R/T790M)-driven tumors.  Compound 3, now renamed CO-1686, is currently in a phase I/II clinical trial in patients with EGFR(mut)-advanced NSCLC that have received prior EGFR-directed therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSdUiOZStIjAqx48Rj5GnGofW6udTcc2ebHZH_UO3VCP7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnis1GjsQ%253D%253D&md5=b42556f3737b33c07511a77ab63ed1d1</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0966&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0966%26sid%3Dliteratum%253Aachs%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DMartin%26aufirst%3DT.%2BS.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DMedikonda%26aufirst%3DA.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DHaringsma%26aufirst%3DH.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520irreversible%2520mutant-selective%2520EGFR%2520inhibitors%2520that%2520are%2520wild-type%2520sparing%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D1468%26epage%3D1479%26doi%3D10.1158%2F1535-7163.MCT-13-0966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. É.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7048</span>, <span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+%C3%89.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lhD4rSyD23o_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2B%25C3%2589.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhD4rSyD23o_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span> <i>FDA Approves New Pill to Treat Certain Patients
with Non-Small Cell
Lung Cancer</i>; <span class="NLM_publisher-name">U.S. Food and Drug Administration</span>, November 13, <span class="NLM_year">2015</span>; <a href="http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm" class="extLink">http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm472525.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+FDA+Approves+New+Pill+to+Treat+Certain+Patients%0Awith+Non-Small+Cell%0ALung+Cancer%3B+U.S.+Food+and+Drug+Administration%2C+November+13%2C+2015%3B+http%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm472525.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs%26jtitle%3DFDA%2520Approves%2520New%2520Pill%2520to%2520Treat%2520Certain%2520Patients%250Awith%2520Non-Small%2520Cell%250ALung%2520Cancer%26pub%3DU.S.%2520Food%2520and%2520Drug%2520Administration%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design of C4-alkyl-1,4-dihydro-2hpyrimido[4,5-<i>d</i>][1,3]oxazin-2-ones as potent and mutant-selective epidermal growth factor receptor (EGFR) L858R/T790M inhibitors</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">3830</span>, <span class="refDoi"> DOI: 10.1038/s41598-017-04184-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1038%2Fs41598-017-04184-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=28630494" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A280%3ADC%252BC1cnpvVKntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2017&pages=3830&author=Y.+Haoauthor=J.+Lyuauthor=R.+Quauthor=D.+Sunauthor=Z.+Zhaoauthor=Z.+Chenauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xuauthor=H.+Li&title=Structure-guided+design+of+C4-alkyl-1%2C4-dihydro-2hpyrimido%5B4%2C5-d%5D%5B1%2C3%5Doxazin-2-ones+as+potent+and+mutant-selective+epidermal+growth+factor+receptor+%28EGFR%29+L858R%2FT790M+inhibitors&doi=10.1038%2Fs41598-017-04184-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors</span></div><div class="casAuthors">Hao Yongjia; Lyu Jiankun; Sun Deheng; Zhao Zhenjiang; Chen Zhuo; Xu Yufang; Li Honglin; Qu Rong; Ding Jian; Xie Hua; Qu Rong</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3830</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) T790M acquired drug-resistance mutation has become a major clinical challenge for the therapy of non-small cell lung cancer.  Here, we applied a structure-guided approach on the basis of the previous reported EGFR inhibitor (compound 9), and designed a series of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-one derivatives as novel mutant-selective EGFR inhibitors.  Finally, the most representative compound 20a was identified, which showed high selectivity at both enzymatic and cellular levels against EGFR(L858R/T790M) (H1975 cell lines) over EGFR(WT) (A431 cell lines).  The representative compound 20a also showed promising antitumor efficiency in the in vivo antitumor efficacy study of H1975 xenograft mouse model driven by EGFR(L858R/T790M).  These results provide a new scaffold for the treatment of dual-mutant-driven non-small cell lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ773w9Z4f3GRFwe7cAcrfPfW6udTcc2eZ-HRCYj_4SsLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnpvVKntw%253D%253D&md5=63f89dc099aae0289c1c39d4549d795d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41598-017-04184-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-017-04184-9%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%26aulast%3DLyu%26aufirst%3DJ.%26aulast%3DQu%26aufirst%3DR.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DStructure-guided%2520design%2520of%2520C4-alkyl-1%252C4-dihydro-2hpyrimido%255B4%252C5-d%255D%255B1%252C3%255Doxazin-2-ones%2520as%2520potent%2520and%2520mutant-selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520L858R%252FT790M%2520inhibitors%26jtitle%3DSci.%2520Rep.%26date%3D2017%26volume%3D7%26spage%3D3830%26doi%3D10.1038%2Fs41598-017-04184-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goto, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuboi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanoda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukai, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kagara, K.</span></span> <span> </span><span class="NLM_article-title">The process development of a novel aldose reductase inhibitor, FK366. part 1. Improvement of discovery process and new syntheses of 1-substituted quinazolinediones</span>. <i>Org. Process Res. Dev.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">700</span>– <span class="NLM_lpage">706</span>, <span class="refDoi"> DOI: 10.1021/op0340661</span> </span><div class="citationLinks">[<a href="/doi/10.1021/op0340661" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BD3sXms1artbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2003&pages=700-706&author=S.+Gotoauthor=H.+Tsuboiauthor=M.+Kanodaauthor=K.+Mukaiauthor=K.+Kagara&title=The+process+development+of+a+novel+aldose+reductase+inhibitor%2C+FK366.+part+1.+Improvement+of+discovery+process+and+new+syntheses+of+1-substituted+quinazolinediones&doi=10.1021%2Fop0340661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The Process Development of a Novel Aldose Reductase Inhibitor, FK366. Part 1. Improvement of Discovery Process and New Syntheses of 1-Substituted Quinazolinediones</span></div><div class="casAuthors">Goto, Shunsuke; Tsuboi, Hiroyuki; Kanoda, Masami; Mukai, Koji; Kagara, Kooji</div><div class="citationInfo"><span class="NLM_cas:title">Organic Process Research & Development</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">700-706</span>CODEN:
                <span class="NLM_cas:coden">OPRDFK</span>;
        ISSN:<span class="NLM_cas:issn">1083-6160</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The novel aldose reductase inhibitor FK366 I is prepd. on multikilogram scale by an improved, practical and cost-effective process.  Addn. of base to a soln. of 2-amino-4-chlorobenzoic acid followed by addn. of sodium cyanate at pH 6-7 and a second treatment with aq. sodium hydroxide yields the quinazoline II; the pH is carefully controlled in the cyanate addn. step by addn. of hydrochloric acid to the reaction mixt., preventing the decompn. of cyanate while allowing the cyclocondensation reaction to occur at a reasonable rate.  Silylation of II with bis(trimethylsilyl)amide in the presence of sulfuric acid (with careful mixing of bis(trimethylsilyl)amide and sulfuric acid to avoid violent reaction) yields an intermediate bis(trimethylsilyloxy)quinazoline which undergoes regioselective alkylation in Et acetate to provide the intermediate III in good yield as a single regioisomer.  Alkylation of the remaining free nitrogen of the quinazoline with 4-bromo-2-fluorobenzyl bromide followed by basic hydrolysis of the ethoxycarbonyl moiety yields I on 35 kg scale.  The dibenzylated quinazoline IV, resulting from incomplete reaction of II in the regioselective alkylation reaction with Et bromoacetate followed by subsequent dibenzylation, acts as a initiator for the formation of an undesired polymorph of I which is difficult to filter and which forms thick slurries.  Seeding solns. of I contg. ≥1% of IV with either polymorph of I results in crystn. of the undesired polymorph of I from soln.  Solns. with 0.5% IV yield different polymorphs depending on the identity of the seed crystal; seeding the soln. with a crystal of the undesired polymorph of I provides crystals of the undesired polymorph of I, while seeding the soln. with a crystal of the desired polymorph of I results in crystn. of the desired polymorph of I.  Monitoring of the initial silylation and regioselective alkylation step by HPLC is used to minimize the amt. of IV present in the final product and thus to provide the desired polymorph of I upon recrystn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIV9IE_Zlkh7Vg90H21EOLACvtfcHk0lhQIdBv1vXhLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXms1artbo%253D&md5=9ef93282259eecc62e8644c0953fd652</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fop0340661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fop0340661%26sid%3Dliteratum%253Aachs%26aulast%3DGoto%26aufirst%3DS.%26aulast%3DTsuboi%26aufirst%3DH.%26aulast%3DKanoda%26aufirst%3DM.%26aulast%3DMukai%26aufirst%3DK.%26aulast%3DKagara%26aufirst%3DK.%26atitle%3DThe%2520process%2520development%2520of%2520a%2520novel%2520aldose%2520reductase%2520inhibitor%252C%2520FK366.%2520part%25201.%2520Improvement%2520of%2520discovery%2520process%2520and%2520new%2520syntheses%2520of%25201-substituted%2520quinazolinediones%26jtitle%3DOrg.%2520Process%2520Res.%2520Dev.%26date%3D2003%26volume%3D7%26spage%3D700%26epage%3D706%26doi%3D10.1021%2Fop0340661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery and structural optimization of N5-substituted 6, 7-dioxo-6, 7-dihydropteridines as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7111</span>– <span class="NLM_lpage">7124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00403</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00403" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7111-7124&author=Y.+Haoauthor=X.+Wangauthor=T.+Zhangauthor=D.+Sunauthor=Y.+Tongauthor=Y.+Xuauthor=H.+Chenauthor=L.+Tongauthor=L.+Zhuauthor=Z.+Zhaoauthor=Z.+Chenauthor=J.+Dingauthor=H.+Xieauthor=Y.+Xuauthor=H.+Li&title=Discovery+and+structural+optimization+of+N5-substituted+6%2C+7-dioxo-6%2C+7-dihydropteridines+as+potent+and+selective+epidermal+growth+factor+receptor+%28EGFR%29+inhibitors+against+L858R%2FT790M+resistance+mutation&doi=10.1021%2Facs.jmedchem.6b00403"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26aulast%3DHao%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DTong%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520and%2520structural%2520optimization%2520of%2520N5-substituted%25206%252C%25207-dioxo-6%252C%25207-dihydropteridines%2520as%2520potent%2520and%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520inhibitors%2520against%2520L858R%252FT790M%2520resistance%2520mutation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7111%26epage%3D7124%26doi%3D10.1021%2Facs.jmedchem.6b00403" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span> <i>Maestro</i>, <span class="NLM_edition">version 9.0</span>; <span class="NLM_publisher-name">Schrödinger, LLC</span>: <span class="NLM_publisher-loc">New York</span>, <span class="NLM_year">2009</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Maestro%2C+version+9.0%3B+Schr%C3%B6dinger%2C+LLC%3A+New+York%2C+2009."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcomputer-program%26sid%3Dliteratum%253Aachs%26jtitle%3DMaestro%26pub%3DSchr%25C3%25B6dinger%252C%2520LLC%26date%3D2009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>– <span class="NLM_lpage">1241</span>, <span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+a+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lhpq1OkpaKbQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520a%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roskoski, R.</span></span> <span> </span><span class="NLM_article-title">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">48</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2015.10.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1016%2Fj.phrs.2015.10.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=26529477" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2016&pages=26-48&author=R.+Roskoski&title=Classification+of+small+molecule+protein+kinase+inhibitors+based+upon+the+structures+of+their+drug-enzyme+complexes&doi=10.1016%2Fj.phrs.2015.10.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes</span></div><div class="casAuthors">Roskoski, Robert</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">26-48</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Because dysregulation and mutations of protein kinases play causal roles in human disease, this family of enzymes has become one of the most important drug targets over the past two decades.  The X-ray crystal structures of 21 of the 27 FDA-approved small mol. inhibitors bound to their target protein kinases are depicted in this paper.  The structure of the enzyme-bound antagonist complex is used in the classification of these inhibitors.  Type I inhibitors bind to the active protein kinase conformation (DFG-Asp in, αC-helix in).  Type I1/2 inhibitors bind to a DFG-Asp in inactive conformation while Type II inhibitors bind to a DFG-Asp out inactive conformation.  Type I, I1/2, and type II inhibitors occupy part of the adenine binding pocket and form hydrogen bonds with the hinge region connecting the small and large lobes of the enzyme.  Type III inhibitors bind next to the ATP-binding pocket and type IV inhibitors do not bind to the ATP or peptide substrate binding sites.  Type III and IV inhibitors are allosteric in nature.  Type V inhibitors bind to two different regions of the protein kinase domain and are therefore bivalent inhibitors.  The type I-V inhibitors are reversible.  In contrast, type VI inhibitors bind covalently to their target enzyme.  Type I, I1/2, and II inhibitors are divided into A and B subtypes.  The type A inhibitors bind in the front cleft, the back cleft, and near the gatekeeper residue, all of which occur within the region sepg. the small and large lobes of the protein kinase.  The type B inhibitors bind in the front cleft and gate area but do not extend into the back cleft.  An anal. of the limited available data indicates that type A inhibitors have a long residence time (minutes to hours) while the type B inhibitors have a short residence time (seconds to minutes).  The catalytic spine includes residues from the small and large lobes and interacts with the adenine ring of ATP.  Nearly all of the approved protein kinase inhibitors occupy the adenine-binding pocket; thus it is not surprising that these inhibitors interact with nearby catalytic spine (CS) residues.  Moreover, a significant no. of approved drugs also interact with regulatory spine (RS) residues.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0COwqC0CabVg90H21EOLACvtfcHk0lhvUEPB6UYajA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslKksL%252FN&md5=e6b45c8644e322f30f898e763780c64b</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2015.10.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2015.10.021%26sid%3Dliteratum%253Aachs%26aulast%3DRoskoski%26aufirst%3DR.%26atitle%3DClassification%2520of%2520small%2520molecule%2520protein%2520kinase%2520inhibitors%2520based%2520upon%2520the%2520structures%2520of%2520their%2520drug-enzyme%2520complexes%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D103%26spage%3D26%26epage%3D48%26doi%3D10.1016%2Fj.phrs.2015.10.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pei, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">2711</span>– <span class="NLM_lpage">2723</span>, <span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">Discovery of pteridin-7(8<i>H</i>)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7821</span>– <span class="NLM_lpage">7837</span>, <span class="refDoi"> DOI: 10.1021/jm401045n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401045n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7821-7837&author=W.+Zhouauthor=X.+Liuauthor=Z.+Tuauthor=L.+Zhangauthor=X.+Kuauthor=F.+Baiauthor=Z.+Zhaoauthor=Y.+Xuauthor=K.+Dingauthor=H.+Li&title=Discovery+of+pteridin-7%288H%29-one-based+irreversible+inhibitors+targeting+the+epidermal+growth+factor+receptor+%28EGFR%29+kinase+T790M%2FL858R+mutant&doi=10.1021%2Fjm401045n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401045n%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520pteridin-7%25288H%2529-one-based%2520irreversible%2520inhibitors%2520targeting%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520kinase%2520T790M%252FL858R%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7821%26epage%3D7837%26doi%3D10.1021%2Fjm401045n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, K.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of 2-oxo-3,4-dihydropyrimido[4,5-<i>d</i>]pyrimidinyl derivatives as new irreversible epidermal growth factor receptor inhibitors with improved pharmacokinetic properties</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">8803</span>– <span class="NLM_lpage">8813</span>, <span class="refDoi"> DOI: 10.1021/jm4012388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8803-8813&author=S.+Xuauthor=T.+Xuauthor=L.+Zhangauthor=Z.+Zhangauthor=J.+Luoauthor=Y.+Liuauthor=X.+Luauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+2-oxo-3%2C4-dihydropyrimido%5B4%2C5-d%5Dpyrimidinyl+derivatives+as+new+irreversible+epidermal+growth+factor+receptor+inhibitors+with+improved+pharmacokinetic+properties&doi=10.1021%2Fjm4012388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%25202-oxo-3%252C4-dihydropyrimido%255B4%252C5-d%255Dpyrimidinyl%2520derivatives%2520as%2520new%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520inhibitors%2520with%2520improved%2520pharmacokinetic%2520properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8803%26epage%3D8813%26doi%3D10.1021%2Fjm4012388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">SHAFTS: a hybrid approach for 3D molecular similarity calculation. 1. Method and assessment of virtual screening</span>. <i>J. Chem. Inf. Model.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">2372</span>– <span class="NLM_lpage">2385</span>, <span class="refDoi"> DOI: 10.1021/ci200060s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ci200060s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVKmtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2011&pages=2372-2385&author=X.+Liuauthor=H.+Jiangauthor=H.+Li&title=SHAFTS%3A+a+hybrid+approach+for+3D+molecular+similarity+calculation.+1.+Method+and+assessment+of+virtual+screening&doi=10.1021%2Fci200060s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">SHAFTS: A Hybrid Approach for 3D Molecular Similarity Calculation. 1. Method and Assessment of Virtual Screening</span></div><div class="casAuthors">Liu, Xiaofeng; Jiang, Hualiang; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Chemical Information and Modeling</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2372-2385</span>CODEN:
                <span class="NLM_cas:coden">JCISD8</span>;
        ISSN:<span class="NLM_cas:issn">1549-9596</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We developed a novel approach called SHAFTS (SHApe-FeaTure Similarity) for 3D mol. similarity calcn. and ligand-based virtual screening.  SHAFTS adopts a hybrid similarity metric combined with mol. shape and colored (labeled) chem. groups annotated by pharmacophore features for 3D similarity calcn. and ranking, which is designed to integrate the strength of pharmacophore matching and volumetric overlay approaches.  A feature triplet hashing method is used for fast mol. alignment poses enumeration, and the optimal superposition between the target and the query mols. can be prioritized by calcg. corresponding "hybrid similarities".  SHAFTS is suitable for large-scale virtual screening with single or multiple bioactive compds. as the query "templates" regardless of whether corresponding exptl. detd. conformations are available.  Two public test sets (DUD and Jain's sets) including active and decoy mols. from a panel of useful drug targets were adopted to evaluate the virtual screening performance.  SHAFTS outperformed several other widely used virtual screening methods in terms of enrichment of known active compds. as well as novel chemotypes, thereby indicating its robustness in hit compds. identification and potential of scaffold hopping in virtual screening.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2vWrL-rCNmrVg90H21EOLACvtfcHk0lhvUEPB6UYajA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVKmtbbO&md5=3733bf9faa6c5ac8945e6ec4a5d365b9</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fci200060s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fci200060s%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DSHAFTS%253A%2520a%2520hybrid%2520approach%2520for%25203D%2520molecular%2520similarity%2520calculation.%25201.%2520Method%2520and%2520assessment%2520of%2520virtual%2520screening%26jtitle%3DJ.%2520Chem.%2520Inf.%2520Model.%26date%3D2011%26volume%3D51%26spage%3D2372%26epage%3D2385%26doi%3D10.1021%2Fci200060s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gong, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ku, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span> <span> </span><span class="NLM_article-title">ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method</span>. <i>Bioinformatics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">1827</span>– <span class="NLM_lpage">1829</span>, <span class="refDoi"> DOI: 10.1093/bioinformatics/btt270</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1093%2Fbioinformatics%2Fbtt270" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=23712658" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVOjsrbN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2013&pages=1827-1829&author=J.+Gongauthor=C.+Caiauthor=X.+Liuauthor=X.+Kuauthor=H.+Jiangauthor=D.+Gaoauthor=H.+Li&title=ChemMapper%3A+a+versatile+web+server+for+exploring+pharmacology+and+chemical+structure+association+based+on+molecular+3D+similarity+method&doi=10.1093%2Fbioinformatics%2Fbtt270"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method</span></div><div class="casAuthors">Gong, Jiayu; Cai, Chaoqian; Liu, Xiaofeng; Ku, Xin; Jiang, Hualiang; Gao, Daqi; Li, Honglin</div><div class="citationInfo"><span class="NLM_cas:title">Bioinformatics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1827-1829</span>CODEN:
                <span class="NLM_cas:coden">BOINFP</span>;
        ISSN:<span class="NLM_cas:issn">1367-4803</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Summary: ChemMapper is an online platform to predict polypharmacol. effect and mode of action for small mols. based on 3D similarity computation.  ChemMapper collects >350 000 chem. structures with bioactivities and assocd. target annotations (as well as >3 000 000 non-annotated compds. for virtual screening).  Taking the user-provided chem. structure as the query, the top most similar compds. in terms of 3D similarity are returned with assocd. pharmacol. annotations.  ChemMapper is designed to provide versatile services in a variety of chemogenomics, drug repurposing, polypharmacol., novel bioactive compds. identification and scaffold hopping studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaSkcKTpsV3rVg90H21EOLACvtfcHk0liMgQf8yuapNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVOjsrbN&md5=b13c728b5b001074ab41315be24231e1</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1093%2Fbioinformatics%2Fbtt270&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fbioinformatics%252Fbtt270%26sid%3Dliteratum%253Aachs%26aulast%3DGong%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DChemMapper%253A%2520a%2520versatile%2520web%2520server%2520for%2520exploring%2520pharmacology%2520and%2520chemical%2520structure%2520association%2520based%2520on%2520molecular%25203D%2520similarity%2520method%26jtitle%3DBioinformatics%26date%3D2013%26volume%3D29%26spage%3D1827%26epage%3D1829%26doi%3D10.1093%2Fbioinformatics%2Fbtt270" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. H. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, X.</span></span> <span> </span><span class="NLM_article-title">New artificial fluoro-cofactor of hydride transfer with novel fluorescence assay for redox biocatalysis</span>. <i>Chem. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">6471</span>– <span class="NLM_lpage">6474</span>, <span class="refDoi"> DOI: 10.1039/C6CC02002J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;key=10.1039%2FC6CC02002J" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2016&pages=6471-6474&author=L.+Zhangauthor=J.+Yuanauthor=Y.+Xuauthor=Y.+H.+P.+Zhangauthor=X.+Qian&title=New+artificial+fluoro-cofactor+of+hydride+transfer+with+novel+fluorescence+assay+for+redox+biocatalysis&doi=10.1039%2FC6CC02002J"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1039%2FC6CC02002J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC6CC02002J%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%2BH.%2BP.%26aulast%3DQian%26aufirst%3DX.%26atitle%3DNew%2520artificial%2520fluoro-cofactor%2520of%2520hydride%2520transfer%2520with%2520novel%2520fluorescence%2520assay%2520for%2520redox%2520biocatalysis%26jtitle%3DChem.%2520Commun.%26date%3D2016%26volume%3D52%26spage%3D6471%26epage%3D6474%26doi%3D10.1039%2FC6CC02002J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J','PDB','4G5J'); return false;">PDB: 4G5J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP','PDB','2RGP'); return false;">PDB: 2RGP</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W2S" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3W2S','PDB','3W2S'); return false;">PDB: 3W2S</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i54"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_47567"></div></div></div></div></div><hr /></hr><p class="last">Also include availability of The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b00346">10.1021/acs.jmedchem.8b00346</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Docked pose of <b>20f</b> and the metabolic stability of <b>20g</b> in human and mouse liver microsomes (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_002.csv">CSV</a>)</p></li><li><p class="inline">Docked <b>5</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>) <a id="rightTab-" class=" internalNav" href="#fig2">Figure <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a>B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Docked <b>7</b>  (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a id="rightTab-" class=" internalNav" href="#fig2">Figure <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a>B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_004.pdb">PDB</a>)</p></li><li><p class="inline">Docked <b>14a</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a id="rightTab-" class=" internalNav" href="#fig2">Figure <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a>C (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_005.pdb">PDB</a>)</p></li><li><p class="inline">Docked <b>20f</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>)<a id="rightTab-" class=" internalNav" href="#fig2">Figure <a id="rightTab-" class=" internalNav" href="#fig2">2</a></a>F (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_006.pdb">PDB</a>)</p></li><li><p class="inline">Docked <b>20f</b> (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2RGP">2RGP</a>) Supporting Information, <a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf">Figure S1</a> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_007.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_001.pdf">jm8b00346_si_001.pdf (481.06 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_002.csv">jm8b00346_si_002.csv (2.01 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_003.pdb">jm8b00346_si_003.pdb (190.91 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_004.pdb">jm8b00346_si_004.pdb (191.98 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_005.pdb">jm8b00346_si_005.pdb (199.82 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_006.pdb">jm8b00346_si_006.pdb (358.08 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b00346/suppl_file/jm8b00346_si_007.pdb">jm8b00346_si_007.pdb (178.69 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b00346&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b00346%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2018.61.issue-13%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b00346" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a5f78fd2d3c5e","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
